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Abstract
DNA vaccines and gene therapies that use plasmid DNA (pDNA) as a vector have gained
attention in recent years for their good safety profile, ease of manufacturing, and potential to treat a
host of diseases. With this interest comes increased demand for high-yield manufacturing processes.
Overall, this thesis aims to develop new, innovative tools for the production of plasmid DNA
biopharmaceuticals.
As one part of this thesis, we designed a 1-mL fed-batch microbioreactor with online monitoring
and control of dissolved oxygen, pH, and temperature, as well as continuous monitoring of cell density.
We used the microbioreactors to scale down temperature-induced production of a pUC-based DNA
vaccine vector, pVAX1-GFP. Scaled-down processes can facilitate high-thoughtput, low-cost bioprocess
development. We found that the microbioreactors accurately reproduced the behavior of a bench-scale
bioreactor as long as key process parameters, such as dissolved oxygen, were held constant across
scales. The monitoring capabilities of the microbioreactors also provided enhanced process insight and
helped identify conditions that favored plasmid amplification.
A second aspect of this thesis involved construction and characterization of a new DNA vaccine
vector based on a runaway replication mutant of the R1 replicon. Runaway replication plasmids
typically show increased amplification after a temperature upshift. However, we found that our new
vector, pDMB02-GFP, gave higher yields during constant temperature culture at 30"C, reaching a
maximum of 19 mg pDNA/g DCW in shake flasks. We gained mechanistic insight into this behavior by
measuring RNA and protein expression levels of RepA, a plasmid-encoded protein required for initiation
of replication at the R1 origin. Through these studies we found that RepA levels may limit plasmid
amplification at 42*C, and relieved this limitation by increasing RepA translation efficiency via a start
codon mutation. We also scaled up production of pDMB02-GFP at 300C from 50-mL shake flasks to 2-L
bioreactors. Initial scale up efforts resulted in increased growth rate compared to the shake flasks,
accompanied by very low plasmid yields. Decreasing the growth rate by limiting dissolved oxygen
increased plasmid specific yield and emerged as a viable strategy for maintaining productivity during
scale up.
Thesis Supervisor: Kristala L. Jones Prather
Title: Associate Professor of Chemical Engineering
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The demand for plasmid DNA (pDNA) is anticipated to increase significantly as DNA vaccines and
non-viral gene therapies enter Phase 3 clinical trials and are approved for use. This increased demand,
along with renewed interest in pDNA as a therapeutic vector, has motivated research targeting the
design of high-yield, cost-effective manufacturing processes. An important aspect of this research is
engineering bacterial strains and plasmids that are specifically suited to the production of plasmid
biopharmaceuticals. This chapter begins with a survey of recent innovations in strain and vector
engineering that aim to improve plasmid stability, enhance product safety, increase yield, and facilitate
downstream purification. Following this in-depth description of the state of the field, the motivation for
pursuing this thesis as well as the thesis aims will be presented. Finally, an outline of the thesis
organization will be discussed.
Parts of this chapter have been published in:
Bower DM, Prather KU. 2009. Engineering of bacterial strains and vectors for the production of plasmid
DNA. Appl Microbiol Biotechnol 82: 805-813.
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1.1 Engineering of bacterial strains and vectors for the production of plasmid
DNA: A literature review
1.1.1 Background
In recent years, great strides have been made toward the development of safe and effective gene
therapies and DNA vaccines for many infectious, acquired, and genetic diseases. Gene therapies act by
transferring DNA to a patient to correct a genetic defect or overexpress a therapeutic protein, while
DNA vaccines use genes to express antigens that elicit a protective immune response. The use of naked
plasmid DNA (pDNA) as a vector for gene-based therapies has been gaining attention in the medical and
biotechnology communities. Currently, 18.5% of gene therapy clinical trials use plasmid DNA as a vector
(www.wiley.co.uk/genmed/clinical). Four veterinary pDNA therapies have been licensed in the US,
Canada, and Australia (Kutzler and Weiner, 2008). As more pDNA-based therapies enter late-stage
clinical trials and are approved for clinical use, the demand for high-quality, pharmaceutical-grade
plasmid DNA is anticipated to increase significantly. Interest in non-viral gene therapy has also been
bolstered by disappointing results from a Phase 2 clinical trial of an adenovirus-based HIV DNA vaccine
(Moore et al., 2008), along with recent advances in delivery vehicles and adjuvants that have increased
the potency of naked pDNA (Saade and Petrovsky, 2012; Sardesai and Weiner, 2011).
From a manufacturing standpoint, the increasing demand for plasmid DNA is coupled to a need
for high-yield, cost-effective production processes. Currently, plasmid DNA is often produced using "off
the shelf' strains of Escherichia coli and plasmid backbones that are known to be effective producers of
recombinant proteins. However, these choices may not be the most favorable when plasmid DNA is the
final product. As a result, significant research efforts are in progress to rationally design bacterial strains
and plasmids specifically suited to the production of plasmid biopharmaceuticals.
The motivation to design new bacterial strains for plasmid DNA production is due in part to the
realization that many common laboratory strains like DH5a and DH10B have undergone a high degree of
12
mutagenesis to improve their performance in cloning, library construction, and/or recombinant protein
production applications. The complex genotypes of many E. coli strains in industrial use today also
greatly hinder the ability to reliably predict the plasmid yield based on the genotype alone. In a survey
of 17 strains of E. coli harboring plasmids ranging in size from 5.8 kb to 20 kb, Yau and colleagues (2008)
found little correlation between strain genotype and plasmid yield. With these factors in mind, many
researchers have used the strategies outlined in Figure 1-1 to develop well-characterized strains for
pDNA production. These strain engineering efforts often seek to preserve the sequence fidelity of both












Figure 1-1. Strain engineering strategies. The parent strain at the center of the diagram represents any E. coli K-12
strain, and the potential modifications to this strain are illustrated. The strain's genome can be modified subtly by
single gene knockouts or implementation of an antibiotic-free selection system. More dramatic modifications such
as genome reduction can be used to remove mobile elements like insertion sequences. Other strategies aim to
ease downstream processing, like expression of heterologous periplasmic nucleases to degrade host genomic DNA
and RNA after cell lysis. Changing the parent strain from K-12 to B has also been investigated to improve pDNA
production. Note that the engineering strategies are shown as independent of one another, but applying several
strategies in parallel to a single strain is possible as well.
Complementing these efforts are alterations in the vector backbone designed to enhance
characteristics such as copy number, genetic fidelity, and segregational stability. Typical plasmid
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backbones used for gene therapeutics have several common features that fall into two categories:
features required for propagation in E. coli and features required for therapeutic efficacy. Elements in
the first category include a bacterial origin of replication, such as the ColE1 origin, and a selective
marker, such as a kanamycin resistance gene. Kanamycin resistance is preferred over a marker that
requires addition of -lactam antibiotics to the culture medium, as these could potentially induce an
allergic response in patients (Butler, 1996). The second category of plasmid features includes the
therapeutic gene and the associated sequences required for its expression in vivo such as a eukaryotic
promoter and poly-adenylation signal. Many vector engineering efforts focus on modifications to the
basic therapeutic backbone as illustrated in Figure 1-2. These modifications aim to improve the
production process by increasing yield, improving product homogeneity and quality, and/or ensuring the
sequence fidelity of the final plasmid product.
Bacterial elements Eukaryotic elements
Remove antibiotic Construct
resistance gene and minicircle DNA to
address safety exclude bacterial
concerns by elements from





- -- - gene
puc
origin ) Eliminate toxic orpolyA mutation-prone
Change origin of sequences to
replication to preserve sequence
increase copy I fidelity and plasmid
number stability
Figure 1-2. Vector engineering strategies. A generic plasmid DNA vaccine or gene therapy vector is shown with
the important features labeled. The bacterial elements required for propagation of the plasmid in E. coli are the
selectable marker (kanamycin resistance gene, Kan R) and the pUC origin of replication. The eukaryotic elements of
the vector required for in vivo efficacy include the eukaryotic promoter/enhancer (Peuk), therapeutic or antigentic
gene, and poly-adenylation signal (polyA). The goal of each vector engineering strategy is described next to the
vector feature targeted for modification.
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This literature review will describe recent developments in strain and vector engineering for the
production of pDNA-based therapies. The state of the field from a clinical perspective has recently been
reviewed (Kutzler and Weiner, 2008). Reviews of vector and insert engineering strategies (Mairhofer
and Grabherr, 2008; Williams et al., 2009a) as well as a review of strain engineering from a metabolic
perspective have also been published recently (Gonealves et al., 2012). This section will survey recent
innovations in strain and vector engineering that aim to improve plasmid stability, enhance product
safety, increase yield, and facilitate downstream purification. While these innovations all seek to
enhance pDNA production, they can vary in complexity from subtle alterations of the host genome or
vector backbone to the investigation of non-traditional host strains for higher pDNA yields.
1.1.2 Engineering to maintain sequence stability
The sequence integrity of a plasmid vector must be controlled during the production process
because of its enormous impact on product safety, yield, and quality. Modifications in the strain and
vector used for production of pDNA can ensure that the sequence and structure of the plasmid is
maintained throughout the duration of the process. The complete sequence of E. coli DH1OB was
recently published (Durfee et al., 2008) and underscores the need for re-evaluation of strains used for
pDNA production. For example, DH10B was found to have a mutation rate 13.5-fold higher than wild-
type E. coli (strain MG1655), mostly due to a significantly higher rate of insertion sequence (IS)
transposition. When compared to MG1655, the DH10B genome contains five additional copies of IS1A
(IS1E)-type transposons which are known to insert into plasmid DNA (Chen and Yeh, 1997). These
findings are especially relevant for pDNA production where the integrity of the final plasmid preparation
is paramount. Contamination of plasmid DNA by mobile elements is a serious regulatory concern, as
these elements can alter the biological properties and safety profile of the vector DNA. This concern is
not purely theoretical - IS1-mediated mutagenesis was recently reported in an industrial process for
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selection of HIV plasmid DNA vaccine candidates. An IS1 insertion in the E. coli DH5 genome was
postulated to be the cause of the presence of a significant population of low plasmid-producing clones
(Prather et al., 2006). Insertion of both an IS1 and an IS5 sequence in the neomycin resistance gene of
the therapeutic plasmid was also observed. Prolonged cultivation in minimal medium may have caused
the high incidence of IS insertion detected in this study, as transposon activity can often be induced by
environmental stressors such as nutrient limitation (Twiss et al., 2005). The population of low-producers
was detrimental to process efficiency by necessitating extensive screening for high-producing clones for
use in master seed banks.
To address the problem of IS-mediated genetic instability, researchers have constructed
multiple-deletion series (MDS) strains of E. coli which contain a significantly reduced genome that is
about 15% smaller than that of the parent strain, MG1655 (Posfai et al., 2006). These strains have all of
the mobile elements removed, and showed no detectable transposon activity when compared to
MG1655 and DH10B. Neither the growth rate of the MDS strains nor their capacity for recombinant
protein production was compromised by the genome reduction. Without insertion sequences, MDS
strains were able to stably maintain plasmids coding for recombinant ectopic fusion proteins and adeno-
associated virus-based plasmids that contain hammerhead secondary structure. Both of these vector
types are often highly unstable in E. coli K-12 strains. Evaluation of the MDS strains in a pDNA
production process has not yet been reported, but the advantages of using these strains is clear and
they have great potential to streamline the production of high-quality, stable pDNA.
Contamination of gene therapeutics by insertion sequences has also been addressed using
vector design solutions. For instance, a plasmid containing the human cystic fibrosis transmembrane
conductance regulator (CFTR) gene for cystic fibrosis therapy showed a high level of segregational
instability due to the expression of toxic peptides from a cryptic E. coli promoter present in the gene
(Boyd et al., 1999). An IS1-containing variant of the vector was discovered in high amounts in some
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fermentations, presumably due to increased fitness via suppression of toxic peptide expression. To
remedy these issues, the researchers inserted an intron near the site of the cryptic promoter that
reduced expression of toxic gene products, thus substantially increasing plasmid stability and decreasing
contamination by IS1 elements.
Changes in plasmid sequence can also be mediated by factors other than IS elements, even in
recombination deficient recA~ strains. For example, vectors that contain direct sequence repeats are
especially vulnerable to recA-independent recombination and can form monomers that have lost one of
the direct repeats and the intervening sequence, as well as head-to-tail combinations of two or three
recombined monomers (Bi and Liu, 1996). This type of recA-independent recombination is thought to
occur through a pathway involving strand mispairing at a stalled replication fork or replication slippage
(Bi and Liu, 1996). A report by Ribeiro et al. (2008) and a follow-up study by Oliveira et al. (2009)
observed this type of recombination in pCineo as well as in a pCIneo-derived rabies DNA vaccine
candidate cultivated in cells exposed to kanamycin. Both plasmids contained two 28-bp direct repeats,
and all three recombination products described above were observed. This recombination conferred
kanamycin resistance, possibly by reducing the distance between the neomycin phosphotransferase
gene and a cryptic E. coli promoter. The kanamycin resistance gene should not have been expressed in
E. coli because it was under the control of the eukaryotic SV40 promoter. These changes in plasmid
structure and aberrant expression of an antibiotic resistance gene represent an obvious safety hazard,
and emphasize the need for detailed sequence analysis of therapeutic vectors to identify and eliminate
mutational hot spots. To aid in this work, Oliveira et al. (2008) have developed an algorithm to predict
the recombination frequency of a plasmid containing a given set of direct repeats. A recent report has
also identified hot spots for repeat-mediated recombination in commonly-used mammalian and
bacterial expression vectors (Oliveira et al., 2010).
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1.1.3 Engineering to promote safety
As discussed in the previous section, it is essential to ensure the sequence fidelity of gene-
based therapeutics that will ultimately be administered to humans. Two other product safety concerns
that can significantly affect the design of a pDNA production process include the use of antibiotics for
plasmid selection and the potential for the therapeutic vector to be transferred to other organisms in
the environment.
In terms of antibiotics, the FDA has long recommended that 1-lactam antibiotics be avoided, as
residual contamination in the final product could potentially cause an allergic reaction in sensitive
individuals (Butler, 1996). Also, antibiotics that are in wide clinical use should be avoided. With these
concerns in mind, the development of antibiotic-free selection systems is desirable from both a cost and
safety perspective - especially as the emergence of antibiotic-resistant pathogens becomes more
common. Several researchers have addressed these concerns by modifying the vector, host, or both to
develop alternative plasmid selection systems. These advances have been reviewed recently
(Vandermeulen et al., 2011), and some key examples are highlighted below.
Several groups have chosen to manipulate essential E. coli genes to ensure efficient killing of
plasmid-free cells. One group chose to target dapD, an essential gene for diaminopimelate and lysine
biosynthesis (Cranenburgh et al., 2001). The endogenous dapD locus was disrupted, and an ectopic
copy of dapD under the control of a lac promoter was integrated into the chromosome. Transforming
this strain with a high copy plasmid containing the lac operator resulted in sufficient titration of lac
repressor away from dapD to give expression of the essential gene. As a result, only cells containing
pDNA with the lac operator sequence survived in culture. This protocol was later adapted to medium
copy number plasmids, like pBR322 (Cranenburgh et al., 2004), and was successfully applied to a
plasmid DNA production process for an HIV DNA vaccine candidate (Hanke and McMichael, 2000). In
other work, Hagg et al. (2004) created a host/vector system where the chromosomal infA gene, coding
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for an essential translation initiation factor, was deleted, and was complemented by a copy of the gene
on the expression vector of interest. A similar system was developed by Vidal et al. (2008) using glyA, an
essential gene for glycine biosynthesis, which allowed only plasmid-bearing cells to grow in minimal
medium without glycine. In both of these studies, the implementation of the antibiotic-free selection
system did not significantly affect the growth rate of the strains.
Goh and Good (2008) overexpressed the essentialfabl gene (enoyl ACP reductase) from a
plasmid, and selected for plasmid-bearing cells using triclosan, a biocide that chemically inhibitsfabl. A
DNA vaccine vector for bovine viral diarrhea virus containing thefab//triclosan selection system showed
comparable immunogenicity to a vector with traditional antibiotic selection (EI-Attar et al., 2012). In the
same study, triclosan was also found to be efficiently removed during plasmid purification to levels
below the assay detection limit. Use of an antidote/poison system has also been investigated in the
context of antibiotic-free recombinant protein or DNA production. Szpirer and Milinkovitch (2005)
constructed an E. coli B strain carrying a chromosomal copy of the ccdB poison gene and selected for
plasmid-bearing cells using vectors containing the ccdA antidote gene. (E. coli B strains are non-
pathogenic laboratory strains that can be used for many of the same applications as K-12 strains, and
the differences between the two strains that are relevant to pDNA production will be discussed below.)
The ccd system is an example of a class of natural plasmid maintenance strategies, known as post-
segregational killing systems, which have been reviewed by Zielenkiewicz and Ceglowski (2001).
Alternative selection systems based on antisense RNA have also recently been investigated.
Dryselius et al. (2003) used a synthetic peptide-nucleic acid complex to inactivate the mRNA from the
chromosomal copy of the essential acpP gene. The strain was rescued by a plasmid containing a copy of
acpP with a mutation that rendered it resistant to the antisense nucleic acid, thus allowing for selection
of plasmid-bearing cells. This selection technique was effective, but is likely to be cost prohibitive at the
large scale owing to the expense of synthesizing the peptide nucleic acid. Mairhofer and colleagues
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(2008) avoided the issue of expense by developing a system that uses the RNA I antisense transcript that
is produced during CoIE1 plasmid replication to regulate expression of an essential host gene. They
integrated an expression cassette containing the essential murA gene (UDP-N-acetylglucosamine
enolpyruvyl transferase) under the control of the pLtetO operator into the chromosome of various E. coli
strains. The tet repressor (tetR) was modified to contain a sequence complementary to RNA 1. In the
presence of a plasmid with a ColEl replicon, tetR was inactivated, allowing expression of the essential
gene. In the absence of a replicating ColEl plasmid, murA expression was repressed, resulting in cell
death. This selection system resulted in higher specific plasmid yields in a fed-batch process compared
to a vector maintained by kanamycin selection (Mairhofer et al., 2010). A major advantage of these
antisense-based systems is that the antibiotic resistance gene can be removed from the plasmid,
resulting in a smaller vector and a reduction in the number of immunostimulatory unmethylated CpG
sequences.
Antibiotic-free selection systems can also be used in conjunction with well-known natural
plasmid stability systems that act by resolving multimers or facilitating plasmid partitioning instead of
killing plasmid-free cells. For example, cer sequences present in natural plasmids like ColEl act with E.
coli host proteins to resolve plasmid multimers in order to prevent multimer accumulation which can
significantly reduce plasmid segregational stability (Summers, 1998). Also, plasmids expressing Par-
family partitioning proteins can help ensure that all daughter cells receive at least one plasmid
(Pogliano, 2002).
A novel vector/host system developed by Soubrier and colleagues (1999) combined antibiotic-
free selection with a plasmid replicon that is dependent on a specifically-engineered host for replication.
This class of plasmids, called pCOR, contains an R6K-derived origin of replication that requires the n
initiator protein encoded by the pir gene. In the system developed by Soubrier et al. (1999) the gene
encoding n was removed from the plasmid and integrated into the E. coli genome. This host-dependent
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replication improves the safety profile of the pCOR vectors by limiting the plasmid host range and thus
significantly reducing the chance of plasmid dissemination to the environment. The pCOR plasmids also
rely on an antibiotic-free, tRNA amber suppressor system for selection, along with a cer sequence to
enhance plasmid stability. In terms of yield, the first-generation pCOR plasmids, which contain a point
mutation in the pir gene to increase copy number, gave yields on the order of 100 mg pDNA/L (Soubrier
et al., 1999). Later work increased the copy number further by additional mutagenesis of pir, producing
yields of 421 mg pDNA/L in a 7-L fed-batch fermentation (Soubrier et al., 2005). The pCOR plasmids
represent the only known published investigation of plasmids containing a non-CoIE1 origin of
replication for use in gene therapy or DNA vaccine applications.
Another method of addressing the safety concerns surrounding bacterial elements in plasmid
biopharmaceuticals is the use of minicircle DNA. Minicircles contain only the transcription unit required
for expression of the therapeutic gene(s), with the bacterial backbone sequences required for
propagation in E. coli removed by site-specific, intramolecular recombination. The construction of
minicircle DNA has been studied for about a decade (Darquet et al., 1997), but feasible production
processes for these vectors have only recently been proposed and with them a new category of vector
and strain engineering challenges. The vector must be engineered to contain the elements necessary
for efficient intramolecular recombination. Two recombination systems currently under investigation
include the phage OC31 integrase gene (Chen et al., 2005) and the parA resolvase (Mayrhofer et al.,
2008) with their associated recognition sites. Both of these systems have the sequence for the required
enzyme integrated into the backbone of the parent plasmid. However, Kay et al. (2010) have recently
reported a variation of their OC31-based system that has the genes for all required enzymes integrated
into the E. coli genome. Tolmachov et al. (2006) have designed a minicircle production system
consisting of an E. coli strain with an arabinose-inducible copy of the Cre recombinase gene integrated
into the chromosome along with a plasmid vector with loxP sites flanking the eukaryotic transcription
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unit. Overall, minicircle DNA represents an attractive alternative to plasmid DNA, especially for gene
therapy applications, because minicircles lack immunostimulatory CpG motifs (and an antibiotic
resistance gene). However, until the production of minicircle DNA can be scaled up and streamlined,
plasmid DNA is likely to remain the preferred vector for non-viral gene therapies.
1.1.4 Engineering to increase plasmid DNA yield
The art of high-density cell culture for pDNA production has been an active area of process
research, often focusing on the development of seed trains (Okonkowski et al., 2005), media (Danquah
and Forde, 2008; O'Kennedy et al., 2000; Wang et al., 2001), and induction strategies (Carnes et al.,
2006). However, strain engineering efforts have also recently begun to address upstream process issues
such as increasing plasmid DNA yield. In an attempt to design an organism better suited to production
of plasmid DNA, researchers have investigated both E. coli B and K-12 strains. B and K-12 strains are
genetically similar, but analysis of mobile elements in a particular B strain showed a very different
profile of insertion sequences. Notably, E. coli B lacks a copy of IS5, and contains 20 copies of IS1 versus
the six to eight usually found in K-12 (Schneider et al., 2002). The lipopolysaccharides (LPS) of K-12 and
B strains both lack the O-antigen. B strains also lack the distal part of the LPS core consisting of D-
galactose, D-glucose, and N-acetyl-D-glucosamine residues (Nikaido, 1996). However, we are not aware
of any studies demonstrating that this difference in polysaccharide content significantly affects the
endotoxin levels in a pDNA production process. Metabolically, derivatives of E. coli B differ from E. coli
K-12 in that B strains typically produce significantly less acetate, even when grown in medium with a
high glucose concentration. This phenomenon has been attributed to a more active glyoxylate shunt
and consequently, more active acetate uptake pathways (Phue et al., 2005).
BL21, a B strain derivative, has been used with great success for overexpression of recombinant
proteins. However, until recently, BL21 has not been considered to be a viable host for pDNA
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production because its genome contains intact endA and recA, resulting in sub-optimal plasmid
preparations. Deleting recA in BL21(DE3) has been shown to improve plasmid segregational stability
(Zhao et al., 2007), but this investigation was conducted in the context of recombinant antibody
production. A recent communication from Phue et al. (2008) reported that with glucose as the carbon
source, BL21ArecA and BL21ArecAAendA produced more pDNA than DH5a. Under these conditions,
BL21-derived strains showed significantly less acetate production and improved glucose utilization, as
expected for a B strain. With glycerol as a carbon source, BL21ArecAAendA performed significantly
better than DH5a in terms of volumetric yield (1904 mg/L versus 991 mg/L), but the differences were
less substantial in terms of specific yield (10.07 mg versus 7.03 mg pDNA per g wet cell weight).
While the study described above found that a strain possessing a more active glyoxylate shunt
(BL21) fared better in high density cell culture and produced more pDNA than a K-12 strain, other
groups have found that disrupting a positive regulator of the glyoxylate shunt, the global transcriptional
regulatorfruR, also led to increased pDNA production. Ow et al. (2006) conducted global transcription
and proteomic analyses to study the differences in metabolism between plasmid-bearing and plasmid-
free E. coli DH5ca cells. As expected, they found that plasmid-bearing cells had a slower growth rate and
an altered profile of central metabolic gene expression when compared to plasmid-free cells. Based on
this work, Ow and colleagues (2007) chose to disrupt thefruR gene in DH5ct and found that this
modification increased growth rate and glycolytic enzyme activity of plasmid-bearing cells along with a
concomitant reduction in gluconeogenesis. The ability to recover a growth rate comparable to plasmid-
free cells is particularly useful in pDNA production, as it reduces the selective pressure against plasmid-
bearing cells and thus increases plasmid stability. In the context of pDNA production, a recent study by
the same group (Ow et al., 2009) found that disruption of fruR led to a 21% increase in specific pDNA
yield from a fed-batch fermentation. Additional strategies for altering host metabolism to improve
pDNA yield have been extensively reviewed by Gongalves et al. (2012).
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1.1.5 Engineering to address downstream processing and purification issues
A key challenge in the development of cost-effective manufacturing processes is improving the
yield of downstream purification steps. Large-scale purification of pDNA is difficult due to the complex,
dynamic structure of pDNA (Prazeres and Ferreira, 2004), viscous process streams (Ciccolini et al., 1998),
and the presence of impurities (e.g. RNA, genomic DNA) with similar properties to the desired product
(Ferreira et al., 2000). One method to improve downstream purification yields is the development of
fermentation processes with high specific pDNA yields which improve overall process yield by increasing
the ratio of plasmid DNA to contaminating biomass. Recent studies have reported yields of 49.1
(Danquah and Forde, 2008) and 51.1 mg/g DCW (Williams et al., 2009b) - significant improvements over
earlier reported values.
Several researchers have taken a different approach and sought to improve downstream
purification by engineering the E. coli host strain to reduce the amount of contaminating genomic DNA
(gDNA) and RNA in the cell lysate. The FDA has yet to set formal lot release criteria for gene-based
therapeutics; however, a generally-accepted specification for product purity is that any residual RNA is
not present in a high enough concentration to be visualized on a 0.8% agarose gel (Horn et al., 1995).
The separation of RNA from DNA is particularly challenging because of the similar physicochemical
properties of both nucleic acids. One strategy for RNA removal is digestion of cell lysates with bovine
RNase A, which allows the resulting small RNA fragments to be more easily separated from DNA.
However, recent concerns surrounding prion-based diseases have precluded the use of animal-derived
enzymes. Cooke et al. (2001) addressed this problem by integrating the gene coding for RNase A into
the chromosome of E. coli JM107 under the control of an IPTG-inducible promoter. After induction, pre-
RNase A was targeted to the periplasm where it folded into its active form and was sequestered from
host nucleic acids. Upon cell lysis, the enzyme was released and efficiently degraded host RNA. This
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strategy was particularly successful because the RNase A enzyme is robust enough to withstand the
conditions of high pH encountered during alkaline lysis.
To address removal of host genomic DNA as well as RNA, Nature Technology Corporation has
developed E. coli hosts expressing periplasmic chimeric proteins that degrade both nucleic acids
(Hodgson and Williams, 2006). These chimeras include the plasmid-safe phage T5 D15 exonuclease
linked to RNase A or S. The exonuclease is "plasmid-safe" in that it specifically degrades linear and
denatured DNA while not affecting the fidelity of supercoiled plasmid DNA. The chimeric proteins can
be reintroduced into the cytoplasm before lysis by inner membrane permeabilization techniques, or can
begin to degrade host nucleic acids immediately after being released by cell lysis. Both of these
schemes significantly reduce the viscosity of the lysate, easing the later stages of purification. This
approach to strain engineering also incorporated autolytic host strains, which have been used previously
for recombinant protein production applications.
While efforts to improve downstream processing focus on strain engineering, they have
addressed many of the major challenges of pDNA production, like separating plasmids from genomic
DNA and host RNA contamination. Continued work in this area has the potential to lower
manufacturing costs by increasing the yield from downstream purification steps.
1.1.6 Future directions
This section described a wide range of strain and vector engineering solutions to problems
facing the production of plasmid DNA for gene therapies and DNA vaccines. As these technologies
mature, they are likely to continue to positively impact the way gene-based therapeutics are produced.
However, there are several other interesting options for improved strains and vectors that have yet to
be investigated. For example, a potential strategy for increasing pDNA yield at an early stage in the
manufacturing process is to increase plasmid copy number. However, surprisingly little work has been
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reported in this area with respect to strain or vector engineering. With the exception of the work on
pCOR (Soubrier et al., 1999; Soubrier et al., 2005) published pDNA production processes exclusively use
high copy number pUC-based plasmids with ColEl origins of replication. Often, plasmid copy number is
modulated using external factors such as temperature (Carnes et al., 2006) to balance the metabolic
burden effects of maintaining high copy number plasmids with the desire for high-yield fermentations.
These external, sometimes resource-intensive, modulations could potentially be eliminated through
rational engineering of the plasmid backbone to increase copy number, or by investigating alternative
origins of replication. In terms of strain engineering, areas of research that could improve production
include removing auxotrophies of existing high pDNA producing strains, as well as engineering a strain
that can maintain high concentrations of supercoiled pDNA. Engineering the structure of the bacterial
outer membrane to reduce endotoxin contamination could also have a significant impact on
streamlining downstream purification of pDNA.
Overall, the strain and vector engineering efforts described in this section demonstrate the
improved processes that can result from re-evaluation of existing technologies and consideration of
process concerns during the basic research phase of product development. While much of the
infrastructure is similar for both recombinant protein and pDNA production, there are many issues that
are specific to a plasmid DNA final product and these issues have been addressed in many original and
innovative ways. As new, engineered strains and vectors continue to be characterized and gain greater
acceptance, implementation of these technologies has great potential to result in more productive
plasmid DNA manufacturing processes.
1.2 Motivation and thesis aims
For nearly two decades, researchers have sought to realize the potential of gene-based
therapies to provide specific and effective treatment for a variety of both infectious and acquired
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diseases. Renewed interest in pDNA-based vaccines has recently been spurred by approval of four
veterinary pDNA-based therapies (Kutzler and Weiner, 2008) and improvement of pDNA delivery via
novel methods such as electroporation (Sardesai and Weiner, 2011). With this renewed interest comes
the need for rationally-designed, high-yield fermentation processes for the production of pDNA. The
overall goal of this thesis is to develop new tools for the production of plasmid DNA biopharmaceuticals.
One crucial aspect of pDNA production is design of the plasmid vector. As demonstrated by the
literature reviewed in the previous section, current manufacturing processes and development efforts
almost exclusively use pUC-based plasmid backbones. This is mostly due to the fact that these vectors
are known to have high copy numbers. There is also a wealth of experience with pUC plasmids from
recombinant protein production. However, it is possible that better alternatives exist, and to this end,
one aspect of this thesis focuses on design of a new DNA vaccine vector. We investigated the potential
of runaway Ri-based plasmids for production of plasmid DNA. This class of plasmids contains replicon
mutations that confer a temperature-induced increase in copy number. The high copy numbers
reported at the shake flask scale (Uhlin et al., 1979) suggest that these vectors could produce yields that
exceed those typically produced by pUC-based plasmids. However, these plasmids have yet to be
investigated in the context of plasmid DNA production.
In the preceding section, we have discussed recent innovations in using engineering approaches
to design strain-vector platforms for plasmid DNA production. With these innovations comes the need
for an effective way to screen new strains and vectors for high productivity. In parallel, there is
increased pressure in the biopharmaceutical industry for faster discovery-to-launch timelines and
reduced research and development costs. To meet these needs, we have designed a process
development tool that combines the high-throughput, low-cost nature of micro-well plates and shake
flasks with the process monitoring and control capabilities of bench-scale bioreactors - a fed-batch,
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micro-scale bioreactor. More specifically, we have used this microbioreactor to scale down and analyze
production of a pUC-based DNA vaccine vector.
Overall, this thesis aims to
* Demonstrate that micro-scale bioreactors can be used as an effective process design tool for a
complex, temperature-inducible process like pDNA production
* Construct a plasmid DNA vaccine vector containing the Ri-based, runaway replication origin and
gain mechanistic insight into its replication
* Develop a bench-scale process for production of the Ri-based vector
1.3 Thesis organization
This thesis is divided into five chapters. Chapter 1 includes a review of the literature describing
recent advances in bacterial strain and vector engineering for improved production of plasmid DNA, as
well as the specific motivation and aims for this thesis work. Chapter 2 describes scale down of
production of a pUC-based DNA vaccine vector using a fed-batch microbioreactor device. We
demonstrated that the 1-mL microbioreactor was a good proxy for a bench-scale bioreactor, and
identified key process parameters that must be held constant to achieve reproducibility across scales.
Chapter 3 presents construction of a new DNA vaccine vector, pDMB02-GFP, containing the runaway R1
replicon and characterization of specific yield profiles of the new vector under various temperature
conditions. We also conducted RNA and protein expression analyses of a key replication control gene to
identify possible factors limiting pDNA yield. In Chapter 4, scale up of pDMB02-GFP production from the
50-mL to 2-L scale is described, including medium development, key scale-up challenges encountered,
and our efforts to mitigate these challenges. Finally, the thesis ends with Chapter 5 which includes





The rising costs of bioprocess research and development emphasize the need for high-
throughput, low-cost alternatives to bench-scale bioreactors for process development. In particular,
there is a need for platforms that can go beyond simple batch growth of the organism of interest to
include more advanced monitoring, control, and operation schemes such as fed-batch or continuous.
We have developed a 1-mL microbioreactor capable of monitoring and control of dissolved oxygen, pH,
and temperature. Optical density can also be measured online for continuous monitoring of cell growth.
To test our microbioreactor platform, we used production of a plasmid DNA vaccine vector (pVAX1-GFP)
in Escherichia coli via a fed-batch temperature-inducible process as a model system. We demonstrated
that our platform can accurately predict growth, glycerol and acetate concentrations, as well as plasmid
copy number and quality obtained in a bench-scale bioreactor. The predictive abilities of the micro-
scale system were robust over a range of feed rates as long as key process parameters, such as dissolved
oxygen, were kept constant across scales.
Parts of this chapter have been published in:
Bower DM, Lee KS, Ram RJ, Prather KU. 2012. Fed-batch microbioreactor platform for scale down and
analysis of a plasmid DNA production process. Biotechnol Bioeng In press. DOI: 10.1002/bit.24498.
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2.1 Introduction
There is increasing pressure in the pharmaceutical industry to accelerate the discovery-to-
launch timelines for therapeutics and to reduce the cost of research and development. It can be difficult
to realize cost savings when dealing with biological therapeutics, as their development often entails
extensive process design and scale-up studies using bench-top bioreactors. Other cheaper, more high-
throughput process development tools exist (shake flasks, micro-well plates), but they often sacrifice
process monitoring and control capabilities for cost and throughput savings.
With these challenges in mind, many researchers have sought to design mini- and
microbioreactors that maintain the control and monitoring capabilities of bench-scale units while
increasing throughput and decreasing capital and labor costs. These developments typically occur in
one of several forms: miniaturized stirred-tank reactors with working volumes on the order of milliliters,
micro-well plates that have been modified to allow online process monitoring and/or nutrient feeding,
or flat-form microfluidic devices with microliter-scale working volumes. The state-of-the-art in
microbioreactor development has been reviewed recently, with articles focusing on the breadth of
available reactor configurations (Betts and Baganz, 2006), as well as advances in process monitoring and
fabrication techniques (Schapper et al., 2009). Another recent article reviewed all of the available small-
scale process development tools and outlined the features that an ideal scale-down system should
contain to meet current biopharmaceutical process development needs (Bareither and Pollard, 2011).
However, only recently have more complex process strategies, such as fed-batch operation,
been investigated at the microscale. Fed-batch processes are common in industrial fermentation and
cell culture as they facilitate a significant increase in biomass under controlled-growth-rate conditions,
often leading to increased productivity. Reports of fed-batch processes at the microscale vary in their
complexity. Isett et al. (2007) achieved feeding in the twenty-four-well pt-24 system (Applikon
Biotechnology Inc.; Foster City, CA) by manually removing the reactor cassette and adding substrate
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aseptically in a biosafety cabinet. Other devices at both the microliter and milliliter scale have used
robotics to intermittently add feed solution to the microreactor cultures (Legmann et al., 2009; Vester et
al., 2009). Siurkus et al. (2010) sought to achieve more continuous feeding using the Enbase controlled-
release technology (Panula-Perala et al., 2008) to mimic a fed-batch process in 96-well plates used for
high-throughput library screening. Implementing a fed-batch process early on allowed the group to not
only select a high-producing cell line, but to ensure that the associated conditions would maintain
productivity upon scale-up. Microfluidics have also been used for nutrient feeding as demonstrated by
Funke et al. (2010). These researchers coupled microfluidic channels to the microtiter plates in the
BioLector system (m2p-labs GmbH; Baesweiler, Germany) to achieve a fed-batch process.
In this work, we have adapted a microbioreactor system originally designed for continuous
culture (Lee et al., 2011) for fed-batch cultivation of Escherichia coli bearing a plasmid DNA vaccine
vector. We chose to study a plasmid production process in the microbioreactors because of its
complexity - plasmid amplification is induced by a temperature shift, and plasmid DNA is an intracellular
product that can only be measured offline. Our microbioreactor is capable of real-time monitoring and
control of pH, dissolved oxygen, and temperature, as well as online measurement of optical density.
Substrate feeding can also be accurately controlled by the system. A working volume of 1000 pL allows
periodic sampling for offline analysis of metabolites and the plasmid DNA product. This work
characterizes the features of our fed-batch microbioreactor and demonstrates its utility as a process
design tool in the context of plasmid DNA production.
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2.2 Materials and Methods
2.2.1 Plasmid and strain
This study used E. coli DH5a [F < 80/acZAM15 A(1acZYA-argF)U169 deoR recAl endAl hsdRl7(rk~,
mk*) phoA supE44 thi-1 gyrA96 relAl X] as a host for the plasmid pVAX1-GFP. pVAX1-GFP is a 3642-bp,
kanamycin-resistant plasmid constructed by cloning the superfolding green fluorescent protein gene
(Pedelacq et al., 2006) into the multi-cloning site of pVAX1 (Invitrogen; Carlsbad, CA), a pUC-based DNA
vaccine vector backbone. DH5a[pVAX1-GFP] frozen seed banks were prepared from mid-exponential-
phase shake flask cultures grown at 300C and stored at -80*C in 15% glycerol.
2.2.2 Culture medium
A semi-defined culture medium was adapted from Listner et al. (2006a). The basal cultivation
medium contained 3 g/L (NH4 )2 SO4 , 3.5 g/L K2HPO 4, 3.5 g/L KH2 PO4 , 10 g/L yeast extract, and 10 g/L
Bacto peptone. 5 g/L glycerol, 8.3 mL/L seed supplement solution, 1 mL/L trace elements solution, and
25 pg/mL kanamycin were added as supplements to the basal medium. The seed supplement solution
contained 60 g/L MgSO 4-7H 20 and 24 g/L thiamine hydrochloride. The trace elements solution
contained 16.2 g/L FeCl 3, 2 g/L ZnCl 2, 2 g/L CoCl 2-6H20, 2 g/L Na2 MoO 4 -2H 2 0, 1 g/L CaCl 2*2H 20, 1.27 g/L
CuCI 2*2H20, and 0.5 g/L H3B03 dissolved in 1.2 N hydrochloric acid. The pH of the basal medium was
adjusted to 7.1 using NaOH. The feed solution for all fed-batch cultures contained 321.4 g/L glycerol
and 79.3 g/L yeast extract.
2.2.3 Plasmid DNA production process
pVAX1-GFP was produced in a process adapted from Carnes et al. (2006) that consisted of three
phases: (1) batch growth on 5 g/L glycerol at 30*C, (2) feeding of a concentrated glycerol/yeast extract
solution at 30 0C, and (3) plasmid amplification at 42*C with continued feeding.
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2.2.4 Microbioreactor device design
The fed-batch microbioreactor device used in this study (Figure 2-1) was a modified version of
the continuous culture device designed by Lee et al. (2011). In contrast to the continuous device, the
fed-batch microreactor has three 15-pL fluid reservoirs connected to the growth chamber via peristaltic
pumps, each with an injection volume of 240 nL. The pumps share the three valves required for
operation (Lee et al., 2011), while the input to the pumps is selected by independent upstream valves
(Figure 2-1B: V2, V3, and V4). In another key adaptation from the continuous culture device, each
reservoir was given a direct connection to the growth chamber by removing the pass-through channel
and combiner before the peristaltic pump. This reduced the time delay between performing an
injection and the injected plug of liquid reaching the growth chamber. As in the continuous device, the
growth chamber consists of three interconnected sections, each with a 500-pL liquid capacity. Using a
working volume of 1000 pL ensured that at most only two of the sections were full at a given time to
facilitate mixing. Oxygenation of the growth chamber was provided by gas diffusion through the PDMS
membrane and was enhanced by mixing (Lee et al., 2006b). Samples for offline analysis were collected
via one of two output ports connected to the growth chamber (Figure 2-1).
Heating was performed at the base of the device using a resistive heater and a digital
temperature sensor calibrated against the temperature of water inside the reactor. Dissolved oxygen
and pH sensing were performed as described by Lee et al. (2011). Optical density was measured
through a 100-pm path length at a wavelength of 590 nm by positioning an LED and photodetector in-
line in a connecting microchannel between two of the growth chamber sections. A smaller path length
enabled linear optical density measurements up to at least OD600 = 50 as measured offline by a DU800
Spectrophotometer (Beckman Coulter; Indianapolis, IN). All optical sensors were measured using fiber
optic probes and data was analyzed in MATLAB to extract measured values. Oxygen and temperature
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control algorithms were implemented using PID control (Lee et al., 2011) while pH control was




















Figure 2-1. (A) Photograph of the fed-batch microbioreactor device with key features indicated. (B) Schematic of
the microbioreactor highlighting details of the liquid flow path and valve design. The dotted boxes indicate that
the valves are shared and act as a single unit. Valves are numbered V1 - V9. V1 controls flow from the solution
input bottles (water, feed, and base); V2, V3, and V4 allow selection of output from pressurized reservoirs; V5, V6,
and V7 comprise the peristaltic pumps; V8 and V9 control output from device. The reservoirs also have a shared
valve for pressurization (not shown).
2.2.5 Microbioreactor cultures
Prior to use, the microbioreactors were placed in heat-sealable PVC bags and sterilized by
gamma-irradiation at 18 kGy. To prepare inoculum for the microbioreactors, 3 mL of semi-defined
medium was inoculated with 0.4% seed bank and grown overnight at 300C. The next day, 3 mL semi-
defined medium was inoculated to an initial OD600 of 0.3 using the overnight culture; 1000 ptL of the
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resultant culture was used to fill the microbioreactor. Dissolved oxygen was controlled by varying the
ratio of oxygen and helium in the inlet gas. Helium was used as the inert gas instead of nitrogen
because its low solubility in water helped to control foaming. pH was controlled at 7.1 using 4 M NaOH.
To better mimic the conditions in the bench-scale reactor, the temperature was slowly increased from
30 0C to 42"C over a period of 30 minutes during the temperature induction phase of the plasmid
production process. An evaporation control scheme was used to compensate for volume lost to
evaporation and sampling. Before the start of feeding, the chip entered evaporation refill mode (Lee et
al., 2011) every 30 minutes. After a sample was taken, the reactor was manually set to evaporation refill
mode to add sterile distilled, de-ionized water until the culture reservoir was full. Evaporation refill was
turned off after the start of feeding (approximately 8 hr after inoculation) to help maintain the reactor
volume at or below 1 mL. Working volumes above 1 mL could result in reduced mixing efficiency.
During the 30 0C feeding phase, the feed addition helped compensate for volume lost due to
evaporation; however, evaporation control was turned back on after the temperature shift (at
approximately 20 hr) to compensate for the higher evaporation rate at the elevated temperature. While
this scheme may have resulted in some transient changes in nutrient concentration, it helped alleviate
the large volume losses observed in runs without any compensation for evaporation. At the end of the
process, the chip could be discarded or gamma-irradiated and re-used.
2.2.6 Bioreactor cultures
Bench-scale bioreactor cultures were performed using a Labfors 3 bioreactor (Infors;
Bottmingen, Switzerland) with a maximum working volume of 2.3 L. The bioreactor was equipped with
a D140 OxyProbe dissolved oxygen sensor (Broadley-James; Irvine, CA) and an F-695 FermProbe pH
electrode (Broadley-James). To prepare the bioreactor inoculum, 3 mL of semi-defined medium was
inoculated with 0.4% seed bank and grown overnight at 30 0C. The next day, 100 mL of semi-defined
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medium was inoculated with 100 iL of overnight culture in a 500-mL baffled shake flask and incubated
overnight at 30*C.
To set up the bioreactor, 1.3 to 1.8 L of basal cultivation medium was autoclaved in the reactor.
On the day of inoculation, medium supplements and 0.2 mL Antifoam 204 (Sigma-Aldrich; St. Louis, MO)
were added, and the reactor was inoculated to an initial OD600 of 0.3 using overnight seed culture. The
dissolved oxygen setpoint was controlled at 35% using a cascade to agitation (250 rpm to 800 rpm), and
air was provided at an initial flow rate of 1 vvm. For oxygen supplementation studies, pure oxygen was
automatically added to the air flow at 0.4 to 0.6 LPM as needed to maintain the DO setpoint. In all runs,
the air flow was increased to 1.2 vvm when the temperature was increased to 420C. pH was controlled
at 7.10 ± 0.05 using 4 M NaOH and 2.25 M H3PO4. Online data was logged using IRIS fermenter log and
control software (Infors). Antifoam was manually added in 0.2-mL increments as needed. Samples were
taken periodically to measure OD60 0 offline using a DU800 Spectrophotometer (Beckman Coulter).
Samples for glycerol, acetate, and plasmid DNA concentration measurements were stored at -30*C until
analysis.
2.2.7 Measurement of glycerol and acetate concentrations
Glycerol and acetate concentrations in culture supernatants were determined using an Agilent
1200 Series HPLC (Agilent Technologies; Santa Clara, CA) equipped with an Aminex HPX-87H column
(Bio-Rad; Hercules, CA). A 5 mM sulfuric acid mobile phase was run at 0.6 mL/min for 25 minutes at
50*C. Glycerol and acetate peaks were detected by refractive index at approximate retention times of
13.4 and 15.2 minutes, respectively.
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2.2.8 Measurement of plasmid copy number
Plasmid copy number was measured using a quantitative PCR (qPCR) assay adapted from the
relative quantitation method described by Lee et al. (2006a). Total DNA (genomic and plasmid) was
isolated from 25-50 pL of culture using the DNeasy Blood & Tissue kit (Qiagen; Valencia, CA). qPCR was
performed using a 7300 Real-Time PCR system (Applied Biosystems; Carlsbad, CA) with primers targeting
the plasmid-based kanamycin resistance gene (forward primer: 5'-TCGACCACCAAGCGAAACA-3', reverse
primer: 5'-CGACAAGACCGGCTTCCAT-3') and dxs, a single-copy gene on the E. coli chromosome
encoding 1-deoxyxylulose-5-phosphate synthase (forward primer: 5'-CGAGAAACTGGCGATCCTTA-3',
reverse primer: 5'-CTTCATCAAGCGGTTTCACA-3'). Each 25-pL qPCR reaction contained 1X Brilliant il
SYBR Green High ROX Master Mix reagent (Agilent Technologies), 200 nM each of the forward and
reverse primers, and the total DNA sample diluted 10- to 100-fold in order to be within the linear range
of the assay. The thermal profile consisted of a 10-minute hold at 95*C followed by 40 cycles of 95 0C for
30 s and 60*C for one minute. Plasmid copy number was calculated using the AACTmethod (Livak and
Schmittgen, 2001) which included normalization to a calibrator plasmid, pVAX1-dxs, containing single
copies of both the kanamycin resistance gene and dxs.
2.2.9 Measurement of plasmid DNA specific yield
Plasmid DNA was quantified from crude lysates prepared from OD600 = 10 cell pellets using the
method described by Listner et al. (2006a). Typically, volumes ranging from 0.2 to 2.5 mL were required
to form a pellet of the appropriate density. The lysis method was modified slightly: cell pellets were
harvested by centrifugation at 5000 x g for 15 minutes, the 37*C incubation took place with 250 rpm
shaking, and 5 pL of 10 mg/mL RNase A solution was used per mL of lysate. The pDNA content of the
lysates was measured using a Gen-Pak FAX anion-exchange column (Waters Corporation; Milford, MA)
on an Agilent 1100 Series HPLC system (Agilent Technologies). Three buffers were used: Buffer A (25
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mM Tris-HCI, 1 mM EDTA, pH 8.0), Buffer B (25 mM Tris-HCI, 1 mM EDTA, 1 M NaCl, pH 8.0), and Buffer
C (0.04 M H3PO4 ). The LC method was run at a constant flow rate of 0.75 mL/min and consisted of the
following steps: (1) linear ramp from 70%:30% A:B to 34%:66% A:B over 10 min., (2) 100% B for 5 min.,
(3) 100% C for 4.5 min., and (4) 70%:30% A:B for 10 min. Plasmid DNA eluted at a retention time of
approximately 11.5 min as detected by absorbance at 260 nm. A standard curve of pVAX1-GFP (2 pg/mL
to 50 pg/mL) was prepared using pDNA purified using the Hi-Speed QlAfilter Plasmid Maxi Kit (Qiagen)
and quantified using a NanoPhotometer (Implen; Westlake Village, CA). A standard curve was used to
calculate the pg of pDNA per mL of lysate prepared from each pellet. Specific yield was calculated using
the correlation that 1 OD600 unit = 0.4 g DCW/L culture.
2.2.10 pDNA quality analysis
Plasmid DNA purified using the Zyppy Plasmid Miniprep Kit (Zymo Research Corporation; Irvine,
CA) was run on a 0.7% agarose gel and stained with ethidium bromide to visualize the relative quantities
of linear, nicked, and supercoiled species. Linear and nicked pDNA standards were made by digesting
pVAX1-GFP with the restriction enzyme Xhol or the nicking endonuclease Nt.BstNB1, respectively.
2.3 Results and Discussion
2.3.1 Plasmid production in bench-scale bioreactors as a model system
A key property of microbioreactors is the ability to predict the behavior of larger scale
fermentations. To evaluate the performance of our fed-batch microbioreactor we used production of a
pUC-based DNA vaccine vector via temperature-induction as a model system. Specifically, we compared
E. coli growth, glycerol consumption, acetate production, and plasmid copy number across scales.
At the bench-scale, initial specific feed rates of 2.6, 3.2, 3.5, and 6.1 g glycerol/L/hr were
investigated. Growth curves show that fed-batch cultures of DH5a[pVAX1-GFP] typically reached OD600
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values between 40 and 60 under the conditions tested (Figure 2-2A). As the feed rate increased, the
final OD600 decreased, likely due to the increased duration of oxygen limitation at higher feed rates.
With air as the only oxygen source, the dissolved oxygen setpoint could not be maintained for the
duration of the run. Higher feed rates led to increased oxygen demand due to increased substrate
availability, and as a result, cultures with higher feed rates became oxygen-limited earlier in the run.
In all bench-scale experiments, the 5 g/L of batched glycerol was consumed before the start of
feeding (Figure 2-2B). At all but the highest feed rate tested, there was no glycerol accumulation in the
medium after the start of feeding. Acetate was produced to varying degrees during the feeding phase,
with the amount of acetate produced increasing with increasing feed rate (Figure 2-2C).
Production of pVAX1-GFP was quantified by measuring the number of plasmid copies per
chromosome (Figure 2-2D). As expected, temperature-induced amplification of pVAX1-GFP occurred in
the bench-scale bioreactor. For the moderate feed rates (3.2 and 3.5 g glycerol/L/hr), the plasmid copy
number remained below 50 copies/chromosome until the temperature shift from 300C to 420C, after
which the copy number steadily increased until the end of the fermentation, reaching maximum values
of 351 and 434 copies/chromosome, respectively. At the highest feed rate, the copy number was about
2-fold higher when the temperature was shifted, but clear temperature-induced amplification still
occurred. At the lowest feed rate, the plasmid copy number only increased from 39 to 62
copies/chromosome over the course of the temperature-induction phase of the culture. Possible
explanations for this phenomenon will be discussed below.
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Figure 2-2. (A) Optical density, (B) glycerol, (C) acetate, and (D) average plasmid copy number profiles for bench-
scale fed-batch cultures with initial specific feed rates of 2.6 (M), 3.2 (0), 3.5 (A), and 6.1 (K) g glycerol/L/hr. In
each plot, from left to right, the arrows indicate the start of feeding and the 30*C-to-42*C temperature shift,
respectively. The plasmid copy number error bars represent the 95% confidence interval calculated from three
replicate wells of the same sample
At the bench scale, we were also able to measure specific pDNA yield from crude lysates. The
final specific yields were 2.9, 4.5, 1.3, and 0.4 mg pDNA/g DCW at initial specific feed rates of 2.6, 3.2,
3.5, and 6.1 g glycerol/L/hr, respectively. There are several possible explanations for the apparent
discrepancies between the copy number and specific yield trends. First, conversion between copy
number and specific yield involves several assumptions, including the cellular chromosomal content and
the number of intact cells contributing to optical density measurements. The average E. coli cell is
typically cited to contain 2.1 chromosomes, however, this value was measured for E. coli B/r during
balanced growth at 37*C, and is not likely to be valid under other growth conditions or for different
strains (Neidhardt and Umbarger, 1996). Chromosomal content changes with growth rate (Bipatnath et
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al., 1998) and growth phase (Akerlund et al., 1995) and a two-fold change in the number of
chromosomes/cell will result in a two-fold change in the expected specific yield calculated from a given
copy number. Due to the complex nature of cell physiology during non-balanced growth, we cannot
calculate the number of chromosomes per cell expected during our fed-batch process. It is also possible
that at higher feed rates, cell debris or partially intact cells containing no pDNA contributed to optical
density measurements, resulting in an artificial lowering of the specific yield. This is supported by the
fact that discrepancies were more prevalent under high-stress culture conditions (oxygen limitation and
high acetate concentration) under which cell morphology likely undergoes the most dramatic change.
Along these lines, it is also possible that stress-induced physiological and morphological changes
reduced the effectiveness of the lysis protocol. Conversely, it is also possible that these physiological
changes resulted in partial occlusion of the genomic DNA such that the qPCR primers could not
efficiently bind, resulting in reduced detection of the chromosomal target. However, gel electrophoresis
analysis of samples from the highest feed rate run showed evidence of increased pDNA concentration
with time (data not shown), lending credence to the idea that the specific yield measurements may not
be accurately capturing pDNA concentrations.
The apparent discrepancy between the trends in copy number and specific yield observed at the
higher feed rates highlights one of the key challenges of microreactor technologies - analytics. The
small sample volumes available from the microreactors preclude the use of the specific yield assay.
However, the qPCR-based copy number assay can be performed at both scales so we chose to make this
our standard for comparison of productivity in the sections that follow.
2.3.2 Plasmid production in microbioreactors
Microbioreactor feed rates of 0.536, 0.664, and 0.868 injections per minute were investigated to
determine the ability of the microreactors to predict trends in growth, metabolite concentration, and
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product yield at the bench scale. The volume of each feed injection was approximately 240 nL, but this
number varied by roughly 20% due to small deviations in the device fabrication process. The injection
rates studied corresponded to specific feed rates of approximately 2.5, 3.1, and 4.0 g glycerol/L/hr.
The growth curves at each feed rate (Figure 2-3A) demonstrate that the microbioreactors can
support cell densities of at least OD600 = 40-60. These cell densities are in the range of those observed
at the bench scale. Note that the trend in optical density with respect to feed rate is inverted for the
microreactors when compared to the bench-scale bioreactor. This is likely due to differences in oxygen
availability. The inlet gas stream to the microreactors was supplemented with oxygen, allowing the
dissolved oxygen level to be maintained at approximately 30% for all feed rates investigated. Therefore,
at higher feed rates, more substrate was available for biomass production and its utilization was not
restricted by the oxygen limitation observed at the bench scale.
The glycerol profiles from the microreactor experiments (Figure 2-3B) show that, in contrast to
the bench-scale runs, there was some glycerol present at the time feeding began. The highest feed rate
resulted in glycerol accumulation, suggesting that the cells were unable to utilize all of the glycerol being
fed. However, the glycerol concentration decreased after the temperature shift, suggesting an increase
in glycerol uptake rate. This is in contrast to the bench-scale reactor in which glycerol accumulated in
the medium monotonically.
The acetate accumulation profiles (Figure 2-3C) highlight a major difference observed between
the micro and bench scales. With the exception of the highest feed rate tested, less than 1 g/L acetate
was produced in the microreactors. This is in stark contrast to the bench-scale reactor in which acetate
accumulated under all conditions tested (Figure 2-2C).
Temperature-induced amplification of pVAX1-GFP was observed at feed rates of 0.536 and
0.664 injections/minute in the microreactors (Figure 2-3D). The final copy number values were about 2-
fold lower than those observed at the bench scale; however, a comparison by agarose gel
42
electrophoresis shows comparable pDNA content across the reactor scales (Figure 2-4: Lanes 4, 5, and
7). At a feed rate of 0.868 injections/minute there was a slight increase in copy number after the
temperature shift, but the increase was not nearly as dramatic as that observed at the lower feed rates
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Figure 2-3. (A) Growth curves for the microbioreactor cultures at feed injection rates of 0.536 (light gray), 0.664
(dark gray), and 0.868 (black) injections per minute. (B) Glycerol, (C) acetate, and (D) average plasmid copy
number profiles for microbioreactor fed-batch cultures with feed injection rates of 0.536 (M), 0.664 (0), and 0.868
(A) injections per minute. In each plot, from left to right, the arrows indicate the start of feeding and the 30*C-to-
420C temperature shift, respectively. The plasmid copy number error bars represent the 95% confidence interval
calculated from three replicate wells of the same sample.
Additional experiments demonstrated that the residual glycerol present at the time of feed
initiation in the microreactor did not impact plasmid copy number (data not shown). Delaying feeding
resulted in a slight increase in the maximum acetate concentration (1.3 g/L compared to 0.5 g/L, both at
20 hr), but the final acetate concentrations with both feeding schemes were nearly identical.
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Another factor that could be contributing to the differences observed between scales is that in
the microreactors the volume was kept approximately constant at 1000 Il throughout the run, and as a
result the specific feed rate remained the same. This is in contrast to the bench-scale reactor in which
the specific feed rate decreased over the course of the fermentation due to the increasing culture
volume.
2.3.3 Plasmid quality assessment
Plasmid DNA quality was evaluated using gel electrophoresis to demonstrate that the
microreactor could produce both comparable quantity and quality (i.e., degree of supercoiling) of the
product. The plasmid produced at both scales was predominantly in the supercoiled form with traces of
the nicked (open-circular) form (Figure 2-4). We can conclude that the microbioreactor cultivation does
not negatively impact plasmid quality, and that the device can be used to evaluate product quality, in
addition to product yield, under a variety of culture conditions.






Figure 2-4. Agarose gel electrophoresis of plasmid DNA produced by the microreactors and bench-scale
bioreactors. Lane 1: DNA ladder with DNA size in kilobases (kb) indicated to the left of the image, Lane 2:
Linearized pVAX1-GFP, Lane 3: Nicked pVAX1-GFP, Lane 4: pVAX1-GFP from bench-scale reactor (3.5 g
glycerol/L/hr), Lane 5: pVAX1-GFP from bench-scale reactor (2.6 g glycerol/L/hr), Lane 6: pVAX1-GFP from
microbioreactor (0.868 inj/min), Lane 7: pVAX1-GFP from microbioreactor (0.536 inj/min). Only a representative
set of pDNA samples is shown. pDNA from all feed rates had quality similar to or better than that shown. All
samples were from the final timepoint of each culture (approximately 30 hours after inoculation). Note also that
the pDNA in Lanes 4, 5, and 7 was purified from OD 60o = 2 pellets, whereas the number of cells used for the pDNA
preparation in Lane 6 was not determined.
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2.3.4 Impact of oxygen availability
One of the most marked differences between the microreactor and bench-scale bioreactor
studies was acetate production. In the microreactors, acetate production was only observed when
glycerol accumulated in the medium, which points to metabolic overflow as the primary cause. In
contrast, acetate was produced in all of the bioreactor runs despite an absence of glycerol accumulation
at all but the highest feed rates. Two common causes of acetate production are metabolic overflow
(i.e., carbon flux that exceeds the capacity of the TCA cycle) and oxygen limitation (Wolfe, 2005).
Elevated temperature has also been shown to induce increased acetate production (Luders et al., 2009).
The degree of metabolic overflow is related to feed rate rather than scale, and the cultures were
exposed to the same temperature extremes at both scales. Therefore, the most plausible explanation
for the differences in acetate production likely involves the oxygen transport properties of each system.
The oxygen mass transfer rate (kLa) in microbioreactors with the same growth chamber geometry as
those used in this work has been measured previously to be approximately 58 hr' (Lee et al., 2011),
which is an order of magnitude lower than values typically achieved in stirred-tank vessels (Bareither
and Pollard, 2011; Islam et al., 2008). To compensate for the lower kLa, the microreactors were always
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Figure 2-5. Dissolved oxygen profiles from representative microbioreactor and bench-scale bioreactor cultures.
(A) Dissolved oxygen profile from microreactor culture with 0.664 inj/min feed rate (black line). A moving average
over a 20-point window is also shown for clarity (light gray line). The inset shows a zoomed-in version of the
dissolved oxygen versus time plot overlaid with the feed injection profile. For each point in the feed injection
profile, a value of 0 indicates that no feed injection took place at that time, while a value of 1 indicates that a feed
injection took place. (B) Dissolved oxygen profiles from bench-scale bioreactor cultures at an initial specific feed
rate of 3.2 g glycerol/L/hr with air only in the inlet gas (black line) and with oxygen supplementation (light gray
line).
In the microreactors, the cultures were never oxygen limited for an extended period of time.
Because of the intermittent nature of the feed injections, the dissolved oxygen dropped sharply
immediately after the injection of substrate, but recovered before the next injection, resulting in an
average dissolved oxygen concentration that was greater than zero (Figure 2-5A). The same was not
true for the bioreactor cultures. At the bench-scale, the setpoint was maintained until the agitation
reached its maximum, at which point the oxygen demand outstripped supply and the dissolved oxygen
dropped to zero (Figure 2-5B). The differences in dissolved oxygen profiles across scales suggest that
acetate accumulation at the bench scale could be due to the culture no longer being fully aerobic.
Alexeeva et al. (2002) have shown that the acetate production rate of a culture increases dramatically
during the transition from aerobic to anaerobic growth. Our hypothesis is also supported by the
detection of fermentation products (formate, lactate, succinate, and ethanol) in the medium at the
highest feed rate (i.e., conditions in which the duration of zero dissolved oxygen was the longest).
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2.3.5 Bench-scale bioreactors with oxygen supplementation
To test the impact of oxygen availability on acetate accumulation and plasmid yield, we
supplemented the inlet air to the bench-scale bioreactor with oxygen in order to maintain the dissolved
oxygen setpoint for the entire run (Figure 2-5B). Two conditions were tested: a moderate feed rate
which did not result in glycerol accumulation (3.2 g glycerol/L/hr initial specific feed rate) and a high
feed rate that resulted in significant glycerol accumulation (6.1 g glycerol/L/hr initial specific feed rate).
The glycerol profile at the moderate feed rate with oxygen supplementation (Figure 2-6B) was the same
as the profile with air only (Figure 2-2B). At the high feed rate, the glycerol profile (Figure 2-6B)
resembled that observed in the microreactors at the highest feed rate tested (Figure 2-3B) -- glycerol
accumulated after the start of the feed, but the concentration decreased after the 30"C-to-420C
temperature shift.
Interestingly, at the moderate feed rate with oxygen supplementation no acetate was produced
after the start of feeding (Figure 2-6C), in contrast to the air-only run at the same feed rate that resulted
in production of approximately 7 g/L acetate (Figure 2-2C). This suggests that oxygen limitation was the
cause of the discrepancies in acetate production between scales. At the high feed rate with oxygen
supplementation, acetate still accumulated in the medium (Figure 2-6C), likely due to metabolic
overflow. This is consistent with the acetate profile seen in the microreactor at the highest feed rate
(Figure 2-3C).
Oxygen supplementation of the bench-scale reactor led to significantly lower plasmid copy
numbers (Figure 2-6D) when compared to the runs with air only in the inlet gas (Figure 2-2D). Some
temperature-induced amplification was observed at both the moderate and high feed rates. The trends
are consistent with those observed in the microreactor, in which the highest feed rate gave the lowest
final copy number (Figure 2-3D). The phenomenon of lower plasmid copy number under non-limiting
oxygen conditions is also consistent with the low copy number observed at the lowest feed rate in the
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air-only bench-scale run (Figure 2-2D). In this run, the dissolved oxygen setpoint could not be
maintained at 30%, but remained above zero for the duration of the run.
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Figure 2-6. (A) Optical density, (B) glycerol, (C) acetate, and (D) average plasmid copy number profiles for oxygen-
supplemented bench-scale cultures with initial specific feed rates of 3.2 (0) and 6.1 (0) g glycerol/L/hr. In each
plot, from left to right, the arrows indicate the start of feeding and the 300C-to-420 C temperature shift,
respectively. Error bars on the plasmid copy number values represent the 95% confidence level calculated from
three replicate wells of the same sample.
The data from the oxygen-supplemented bioreactors clearly demonstrate that our fed-batch
microbioreactor platform can replicate a complex bench-scale fed-batch process as long as key process
parameters (i.e., oxygen availability) are held constant across scales. We have shown that the dissolved
oxygen profiles under standard operating conditions can be quite different at the bench and micro-
scale, and that results were only consistent across scales when these differences were accounted for.




To simulate the oxygen limitations observed at the bench scale and further test our devices, we
ran microbioreactors at a feed rate of 3.1 g glycerol/L/hr using air alone or helium containing a
maximum of 50% oxygen as the inlet gas. We found that acetate accumulated to concentrations of
about 17 g/L (Figure 2-7A). We expected a significant increase in plasmid copy number, similar to that
observed in the air-only bench-scale runs, but only a slight amount of plasmid amplification was
observed (Figure 2-7B). Careful analysis of the runs showed that the high concentrations of acetate
resulted in a very low pH by the end of the run (5.8 - 6) due to a combination of technical problems with
the pH sensor and the limited volume available for base addition.
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Figure 2-7. (A) Acetate and (B) plasmid copy number profiles from microbioreactor runs at a feed rate of 3.1 g
glycerol/L/hr with air only (A) or a maximum of 50% oxygen (l) in the inlet gas. In each plot, from left to right,
the arrows indicate the start of feeding and the 30OC-to-42 0 C temperature shift, respectively. Error bars on the
plasmid copy number values represent the 95% confidence level calculated from three replicate wells of the same
sample.
To test the hypothesis that acidic pH was negatively affecting plasmid copy number, we ran two
bench-scale fermentations at an initial specific feed rate of 5.5 g glycerol/L/hr. In one run, the pH was
controlled at 7.1 for the entire experiment. In the other, the pH was controlled at 7.1 until the
temperature shift, at which time the pH was shifted to 6.0. Under both pH conditions, acetate
accumulation levels (Figure 2-8A) were comparable to those in the oxygen-limited microreactor
experiments (Figure 2-7A). These similar profiles likely resulted from the higher feed rate used in the
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bioreactor runs (and the resulting higher oxygen demand) counterbalancing the effects of the higher kLa
of the bioreactors. Metabolic overflow also likely contributed to acetate production in all runs, as
glycerol accumulated in the medium at both scales (data not shown). In terms of plasmid production,
the results show that acidic pH at the end of the process resulted in a significant decrease in plasmid
copy number compared to the run controlled at a neutral pH (Figure 2-8B).
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Figure 2-8. (A) Acetate and (B) plasmid copy number profiles from fed-batch bioreactor cultures with (0) and
without (0) a pH downshift from 7.1 to 6.0 at t = 20 hr. From left to right, arrows indicate the start of feeding and
the 30*C-to-42*C temperature shift, respectively. Error bars represent the 95% confidence level calculated from
three replicate wells.
There is some evidence in the literature that acidic pH can negatively impact plasmid yield,
possibly due to a reduction in the proton motive force and the resulting drop in ATP production
(Ongkudon et al., 2011). However, another study observed a modest improvement in plasmid titers at
slightly acidic pH values (O'Mahony et al., 2007). Despite these conflicting results, the observations
made in this work emphasize the importance of being vigilant about changes in all process parameters
during a scale-down effort, as they may have a significant impact on productivity.
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2.4 Conclusions
In this work, we demonstrated the design and implementation of a 1-mL microbioreactor for
scale-down of a complex, fed-batch process. Our microreactor provided monitoring and control of
dissolved oxygen, pH, and temperature, as well as continuous monitoring of optical density. Using the
model system of temperature-induced production of a plasmid DNA vaccine vector in E. coli we showed
that the microbioreactor can accurately reproduce the growth, metabolite profiles, and plasmid
amplification observed at the bench-scale under comparable conditions. We varied the feed rate to
demonstrate that the results were reproducible across scales under conditions in which the primary
substrate (glycerol) was limiting or in excess. We also observed that plasmid copy number appeared to
be higher under "non-optimal" conditions (low dissolved oxygen, acetate accumulation), and is
negatively impacted by acidic pH. These key parameters would not have been identified without the
use of the scale-down system. By extending our process monitoring beyond growth and including
metabolites and product yields as indicators of scale-down accuracy, we were able to gain a better
understanding of the process as a whole.
Over the course of our investigation, we identified several differences between scales, such as
volume changes with feeding (or lack thereof). However, the qualitative agreement between the bench-
and micro-scale data indicates that these differences are not critical for the utility of the microreactor
system. In addition, oxygen availability emerged as a key parameter to achieve consistency during scale-
down. The increased ease and safety of using oxygen supplementation at the microscale led us to
uncover this key process requirement. Various input gas mixtures could be explored in the
microreactors to further investigate the impact of oxygen availability on culture productivity.
Overall, we have demonstrated the successful scale down of a temperature-inducible, fed-batch
process for plasmid DNA production in E. coli from 2 L to 1 mL. Our microbioreactor device includes
many of the key features required to meet the current needs of microbial process development in the
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biopharmaceutical, biomaterials, and biofuels industries. These features include advanced process
monitoring and control capabilities, well-controlled feeding, sufficient oxygen transfer to achieve high
cell densities, and rapid set-up and clean-up. Current and future work seeks to parallelize the devices to
allow a single researcher to run multiple experiments simultaneously.
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Chapter 3
New plasmid DNA vaccine vectors with Ri-based replicons
Abstract
There has been renewed interest in biopharmaceuticals based on plasmid DNA (pDNA) in recent
years due to approval of several veterinary DNA vaccines, on-going clinical trials of human pDNA-based
therapies, and significant advances in adjuvants and delivery vehicles that have helped overcome earlier
efficacy deficits. In this work, we have constructed a new DNA vaccine vector, pDMB02-GFP, containing
the runaway R1 origin of replication. The runaway replication phenotype should result in plasmid copy
number amplification after a temperature shift from 300C to 420C. However, using Escherichia coli DH5a
as a host, we observed that the highest yields of pDMB02-GFP were achieved during constant-
temperature culture at 30*C, with a maximum yield of approximately 19 mg pDNA/g DCW being
observed. By measuring mRNA and protein levels of the RI replication initiator protein, RepA, we
determined that RepA may be limiting pDMB02-GFP yield at 42*C. A mutant plasmid, pDMB-ATG, was
constructed by changing the repA start codon from the sub-optimal GTG to ATG. In cultures of
DH5a[pDMB-ATG], temperature-induced plasmid amplification was more dramatic than that observed
with pDMB02-GFP, and RepA protein was detectable for several hours longer than in cultures of
pDMB02-GFP at 420C. Overall, we have demonstrated that Ri-based plasmids can produce high yields
of high quality pDNA without the need for a temperature shift, and have laid the groundwork for further
investigation of this class of vectors in the context of plasmid DNA production.
Parts of this chapter are in preparation for publication in:
Bower DM, Prather KU. Development of new plasmid DNA vaccine vectors with Ri-based replicons.
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3.1 Introduction
Gene therapies and DNA vaccines have gained attention in recent years as potential treatments
for a range of acquired and infectious diseases. In particular, plasmid-DNA-based therapies are
attractive because they have a good safety profile and are relatively easy to manufacture using
Escherichia coli as a host. Interest in the field has also been stimulated by the approval of several
veterinary pDNA-based therapeutics and on-going clinical trials of plasmid-based human therapeutics
(Kutzler and Weiner, 2008). In addition, a recent Phase 2 trial of an adenoviral-vectored DNA vaccine
yielded disappointing results (Moore et al., 2008), fueling safety and efficacy concerns surrounding
adenoviral vaccines. Finally, recent advances in delivery vehicles and adjuvants for use in concert with
naked plasmid DNA have helped increase the efficacy of these therapies (Saade and Petrovsky, 2012).
Gene delivery via electroporation has especially reinvigorated the field; early studies suggest that DNA
delivered using electroporation devices may elicit immune responses on par with more traditional
vaccines (Sardesai and Weiner, 2011).
Currently, plasmid DNA is produced almost exclusively using vectors containing the high-copy
pUC replicon. pUC-based plasmids are derivatives of the ColEl origin of replication that lack the RNA
one modulator (Rom) protein and contain a point mutation in the RNA 11 sequence. These two
mutations together give increasingly higher copy numbers as the culture temperature is increased from
30 0C to 420C (Lin-Chao et al., 1992). Extensive process development has resulted in the design of very
high yield, fed-batch processes for the production of pUC vectors (Williams et al., 2009b). However,
with the exception of the pCOR family of plasmids based on the R6K replicon (Soubrier et al., 1999;
Soubrier et al., 2005), no other plasmid replicons have been investigated for pDNA production
applications.
One promising alternative to the currently-available plasmids are vectors based on the so-called
runaway R1 origin of replication. There are numerous reports in the early plasmid literature about these
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high-copy mutants of the E. coli plasmid R1. Runaway replication plasmids lose control of their copy
number at high temperatures (> 37*C), resulting in plasmid copy numbers as high as 2000 copies per
chromosome (Uhlin et al., 1979). The mechanism of R1 replication has been described extensively
elsewhere (Nordstr6m, 2006). In short, two point mutations confer the runaway replication phenotype:
one that decreases transcription of the antisense RNA repressor copA, and a second that increases
transcription of the replication initiator protein gene, repA, in a temperature-dependent fashion
(Givskov et al., 1987). Runaway Ri-based plasmids have been used successfully for temperature-
induced recombinant protein production (Ansorge and Kula, 2000; Hoffmann et al., 1987; Kidwell et al.,
1995; Morino et al., 1988), but they have yet to be investigated in the context of plasmid DNA
production for therapeutic applications.
This chapter describes the construction and characterization of a new DNA vaccine vector,
pDMB02-GFP, containing the runaway Ri origin of replication that is capable of producing high plasmid
DNA yields. The yield trends of our new vector were compared to the yields of both the replicon source
plasmid and a pUC-based DNA vaccine vector at the shake flask scale in rich medium. We also
monitored the mRNA and protein expression of the plasmid replication initiator, repA, to gain insight
into the observed yield trends.
3.2 Materials and Methods
3.2.1 E. coli strains and plasmids
E. coli strain DHSa [F 480/acZAM15 A(IacZYA-argF)U169 deoR recAl endAl hsdR17(rk~, mk+)
phoA supE44 thi-i gyrA96 re/Al V] and the plasmid pVAXI (2999 bp) were purchased from Invitrogen
(Carlsbad, CA). pVAX1-GFP (3642 bp) was constructed by cloning the superfolding green fluorescent
protein (sGFP) gene (Pedelacq et al., 2006) into the multi-cloning site of pVAX1. The sGFP gene was
obtained from the plasmid pTrcsGFP, a gift from the Gregory Stephanopoulos laboratory. pCP40 (5029
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bp) was constructed by Remaut et al. (1983) and was obtained from the Belgian Coordinated Collections
of Microorganisms BCCM/LMBP plasmid collection (accession number LMBP 951).
To construct pDMB02-GFP, a 1938-bp fragment of pVAX1 containing the human
cytomegalovirus (CMV) immediate-early promoter/enhancer, bovine growth hormone (BGH)
polyadenylation signal, and kanamycin resistance gene was PCR-amplified using primers containing Avrll
and Sbfl restriction sites. A 3073-bp fragment of pCP40 containing the RI origin of replication along
with the repA, copA, and copB gene sequences was also PCR-amplified with the same restriction sites.
The pVAX1 and pCP40 fragments were ligated to construct the plasmid pDMB02. The sGFP gene was
cloned into the Nhel and Xhol restriction sites downstream of the CMV promoter/enhancer. A Kozak
sequence was also inserted at the start of the sGFP gene by adding the sequence ACC before the start
codon and a valine codon (GTG) following the start codon. The Kozak sequence should help facilitate
sGFP gene expression in mammalian cells (Kozak, 1987). The resulting vector, pDMB02-GFP, was 5668











Figure 3-1. Feature map of pDMB02-GFP. DNA vaccine vector features: kanamycin resistance marker (KanR),
human cytomegalovirus immediate-early promoter/enhancer (PCMV), superfolding GFP gene (sGFP), bovine
growth hormone polyadenylation signal (BGH PolyA). R1 replicon features: copy number control genes (repA,
copA, copB), origin of replication (R1ori). The locations of the point mutations that confer the runaway replication
phenotype are also indicated (RR1, RR2).
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The start codon of repA in pDMB02-GFP was mutated from GTG to ATG using site-directed
mutagenesis resulting in the plasmid pDMB-ATG. Primers containing the mutation were used to amplify
pDMB02-GFP using 20 cycles of PCR with Phusion high-fidelity DNA polymerase (New England Biolabs;
Ipswich, MA). The primers were purified using a reverse phase cartridge by the vendor (Sigma-Aldrich;
St. Louis, MO) and their sequences are shown below:
5'-GTGAAGATCAGTCATACCATCCTGCACTTACAATGCG-3'
5'-GCAGGATGGTATGACTGATCTTCACCAAACGTATTACCG-3'
After PCR, the template plasmid was digested using Dpnl, and after clean-up the reaction was used to
transform ElectroMAX DH10B cells (Invitrogen). Positive transformants were selected on LB/agar plates
containing 50 pg/mL kanamycin, and the presence of the start codon mutation was verified by
sequencing.
3.2.2 Preparation of working seed banks
Frozen working seed banks of DH5a[pDMB02-GFP] and DH5a[pDMB-ATGI were prepared by
transforming subcloning-efficiency, chemically-competent DH5a (Invitrogen) with purified plasmid.
Positive transformants were selected on LB/agar plates containing 25 pg/mL kanamycin. After overnight
incubation at 300C, a single colony was used to inoculate 3 mL of LB medium containing 25 pg/mL
kanamycin. The culture was incubated overnight at 300C. The next day, 500 pL of overnight culture was
used to inoculate 50 mL of LB medium containing 25 ig/mL kanamycin in a 250-mL shake flask. The
culture was incubated at 300C until mid-exponential phase (OD600 approximately equal to 0.5), at which
time 900 pL of culture was added to 900 pL of cold 30% (v/v) glycerol in a cryogenic vial and immediately
stored at -80 0C. Working seed bank vials were discarded after two freeze-thaw cycles.
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3.2.3 Culture conditions
Difco LB Broth, Miller (BD; Franklin Lakes, NJ) was used for shake flask cultures and contained 10
g/L tryptone, 5 g/L yeast extract, and 10 g/L NaCl. Cell density was monitored using OD600
measurements on a DU800 spectrophotometer (Beckman Coulter; Indianapolis, IN). All cultures were
mixed and aerated by agitation at 250 rpm unless otherwise specified.
Temperature shift experiments
Temperature-induced plasmid amplification was studied using temperature shift experiments as
follows: 100 to 110 mL of LB medium containing 25 pg/mL kanamycin was inoculated to an initial OD600
= 0.00025 using a working seed bank. The very low initial OD600 was chosen to avoid glycerol carry-over
from the working seed bank vial. The cultures were incubated in 500-mL baffled shake flasks at 30"C
until the desired growth phase was achieved (typically OD600 = 0.5 - 1.0) at which point half of the
culture volume was transferred to a 250-mL baffled shake flask and incubated at 42*C. The remaining
culture was transferred to a 250-mL shake flask and incubated at 30*C.
Seed growth phase study
5 mL LB containing 25 pg/mL kanamycin was inoculated with 20 pL of DH5a[pDMB02-GFP]
working seed bank and incubated at 30"C. Aliquots of the culture were collected in late exponential
(OD 600 = 1.1), early stationary (OD600 = 2.3), and late stationary (OD600 = 2.8) growth phases and used to
inoculate 50 mL LB containing 25 pg/mL kanamycin to an initial OD600 = 0.01. The resulting cultures
were incubated at 300C for at least 24 hours. Samples were taken periodically to measure cell growth
and plasmid production.
3.2.4 Measurement of plasmid copy number
Plasmid copy number was measured using a quantitative PCR (qPCR) assay adapted from the
relative quantitation method described by Lee et al. (2006a). Total DNA (genomic and plasmid) was
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isolated from 100 pL of culture using the DNeasy Blood & Tissue kit (Qiagen; Valencia, CA). qPCR was
performed using a 7300 Real-Time PCR system (Applied Biosystems; Carlsbad, CA) with primers targeting
the plasmid-based kanamycin resistance gene (forward primer: 5'-TCGACCACCAAGCGAAACA-3', reverse
primer: 5'-CGACAAGACCGGCTTCCAT-3') and dxs, a single-copy gene on the E. coli chromosome
encoding 1-deoxyxylulose-5-phosphate synthase (forward primer: 5'-CGAGAAACTGGCGATCCTTA-3',
reverse primer: 5'-CTTCATCAAGCGGTTTCACA-3'). Each 25-pL qPCR reaction contained 1X Brilliant Il
SYBR Green High ROX Master Mix reagent (Agilent Technologies; Santa Clara, CA), 200 nM each of the
forward and reverse primers, and the total DNA sample diluted 5-fold (if necessary) in order to be within
the linear range of the assay. The thermal profile consisted of a 10-minute hold at 95*C followed by 40
cycles of 95"C for 30 s and 60*C for one minute. Plasmid copy number was calculated using the AACT
method (Livak and Schmittgen, 2001) which included normalization to a calibrator plasmid, pVAX1-dxs,
containing single copies of both the kanamycin resistance gene and dxs.
3.2.5 Measurement of plasmid DNA specific yield
Plasmid DNA was quantified from crude lysates prepared from OD600 = 10 cell pellets using the
method described by Listner et al. (2006a). The lysis method was modified slightly: cell pellets were
harvested by centrifugation at 5000 x g for 15 minutes, the 37 0C incubation took place with 250 rpm
shaking, and 5 iL of 10 mg/mL RNase A solution was used per mL of lysate. The pDNA content of the
lysates was measured using a Gen-Pak FAX anion-exchange column (Waters Corporation; Milford, MA)
on an Agilent 1100 Series HPLC system (Agilent Technologies). Three buffers were used: Buffer A (25
mM Tris-HCI, 1 mM EDTA, pH 8.0), Buffer B (25 mM Tris-HCI, 1 mM EDTA, 1 M NaCI, pH 8.0), and Buffer
C (0.04 M H3 PO4). The LC method was run at a constant flow rate of 0.75 mL/min and consisted of the
following steps: (1) linear ramp from 70%:30% A:B to 34%:66% A:B over 10 min., (2) 100% B for 5 min.,
(3) 100% C for 4.5 min., and (4) 70%:30% A:B for 10 min. Plasmid DNA eluted at a retention time of
59
approximately 11.5 min as detected by absorbance at 260 nm. A standard curve of pVAX1-GFP (2 pg/mL
to 50 pg/mL) was prepared using pDNA purified using the Hi-Speed QiAfilter Plasmid Maxi Kit (Qiagen)
and quantified using a NanoPhotometer (Implen; Westlake Village, CA). The standard curve was used to
calculate the pg of pDNA per mL of lysate prepared from each pellet. Specific yield was calculated using
the correlation that 1 OD600 unit = 0.4 g DCW/L culture.
3.2.6 Quantitative real-time PCR
RNA was purified from OD60 = 1 pellets using the Illustra RNAspin Mini RNA Isolation Kit (GE
Healthcare; Piscataway, NJ). 1 g/L lysozyme was used for cell lysis in the first step of the protocol. Due
to the high plasmid DNA content of the strains used in this work, an additional DNase digestion was
required after the RNA purification step to remove contaminating DNA. 43 PL purified RNA was
digested with 2 pL DNase I (New England Biolabs) in 5 pL of the supplied reaction buffer for 10 min. at
37 0C. RNA was purified from the other reaction components using the RNA Cleanup protocol from the
RNeasy Mini Kit (Qiagen). The RNA content of each sample was measured using a NanoPhotometer
(Implen), and 800 ng of RNA was converted to cDNA using the QuantiTect Reverse Transcription Kit
(Qiagen). Control reactions containing water instead of the reverse transcriptase enzyme were included
for each sample.
Quantitative PCR was performed on a 7300 Real-Time PCR System (Applied Biosystems). The
desired reference sample was diluted 2- to 1000-fold to prepare a standard curve. repA mRNA was
detected using gene-specific primers (forward primer: 5'-CAGAGCTTAAGTCCCGTGGAAT-3', reverse
primer: 5'-TGACGTTCTCTGTTCGCATCA-3') designed by Primer Express 3.0 software (Applied
Biosystems). Each 25-pL reaction contained 1X Brilliant 11 SYBR Green QPCR High ROX Master Mix, 200
nM each of the forward and reverse primers, and the experimental sample diluted 100-fold. The
thermal cycling conditions were a 95*C hold for 10 min., followed by 40 cycles of 950C for 30 sec. and
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60 0C for 1 min. Dissociation-curve analysis was also performed to check for the presence of primer
dimers or non-specific products. Results were analyzed using the Applied Biosystems Sequence
Detection Software (v. 1.3.1).
3.2.7 Immuno-detection of RepA protein
Removal of cross-reactive antibodies from RepA antiserum
Polyclonal RepA antiserum was a generous gift from Prof. Rafael Giraldo (Centro de
Investigaciones Biol6gicas, Madrid, Spain) and was prepared from rabbits as described by Giraldo-Sudrez
et al. (1993). To reduce background binding, the RepA antiserum was incubated with plasmid-free DH5ct
lysate to precipitate non-specific E. co/i-reactive antibodies. A lysate of plasmid-free DH5a was prepared
from 50 mL of mid-exponential phase culture grown in LB medium by freeze-thaw and sonication in
buffer containing 10 mM Tris-HCI at pH 7.5, 140 mM NaCl, 1% Triton X-100, 1% BSA, 1% sodium
deoxycholate, and 1 Complete Mini Protease Inhibitor Cocktail tablet (Roche; Indianapolis, IN) per 10
mL. The DH5a lysate was added to an aliquot of RepA antiserum in a 1:1 ratio and incubated at room
temperature for 5.5 hr with gentle rocking. After incubation, the antisera was centrifuged for 20 min. at
20000 x g and 40C. The supernatant was recovered and stored in single-use aliquots at -80 0C.
Cell lysis
Cell lysates were prepared by resuspending pellets from 4-5 mL of culture in 1 mL 10 mM Tris-
HCI at pH 8.0. The 1-mL suspension was added to approximately 500 pL of 0.1 mm glass beads
(Scientific industries; Bohemia, NY) in a 1.7-mL microcentrifuge tube. The suspension and glass beads
were vortexed at maximum speed for 5 min. followed by centrifugation for 20 min. at 14000 x g and 40C.
The supernatant was recovered and stored at -300C.
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SDS-PAGE
Total protein content of the lysates was measured using the modified Bradford assay described
by Zor and Selinger (1996). A 7.5-pl aliquot of each lysate containing 2 pg total protein (balance water)
was prepared. An equal volume of Laemmli buffer containing 5% (v/v) B-mercaptoethanol was added to
each aliquot, and the samples were incubated at 100*C for 5 min. Samples were loaded on a 10% Mini-
PROTEAN TGX Gel with 15 x 15-pL wells (Bio-Rad; Hercules, CA) and run at 200 V for 30 min in
tris/glycine/SDS buffer.
Western blots
Protein separated by SDS-PAGE was transferred to a nitrocellulose membrane (Pall Corporation;
Pensacola, FL) for 1 hr at 100 V using a Mini Trans-Blot Electrophoretic Transfer Cell (Bio-Rad) with
transfer buffer containing 25 mM Tris, 192 mM glycine, and 20% (v/v) methanol at pH 8.3. After
transfer, the membrane was blocked with a 5% (w/v) bovine serum albumin solution prepared in TBS
(2.42 g/L Tris, 29.24 g/L NaCl, pH 7.5) at room temperature for 2 hr. After two 10-min. washes with
TBST solution (TBS + 0.05% v/v Tween-20), the membrane was incubated with a 1:1000 dilution of RepA
antiserum in TBS containing 10% glycerol for 2 hr at room temperature. The membrane was washed
three times with TBST for 10 min. each, and was then incubated with a 1:5000 dilution of goat anti-
rabbit IgG-HRP secondary antibody (Santa Cruz Biotechnology; Santa Cruz, CA) in TBS for 1 hr. After two
10-minute washes with TBST and one 10-minute wash with TBS, secondary antibody binding was
visualized using Western Blotting Luminol Reagent (Santa Cruz Biotechnology) following the
manufacturer's instructions.
3.2.8 Cloning and expression of repA
To verify that the band being detected on the Western blots was indeed RepA, a positive control
vector was constructed by cloning the repA gene into the BamHl/Hindlll sites of pETDuet-1 (EMD
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Millipore; Billerica, MA), in-frame with an N-terminal 6X His tag. The resulting plasmid, pETDuet-repA,
was used to express RepA-His in E. coli BL21 Star (DE3) (Invitrogen). 50-mL LB cultures of BL21 Star
(DE3) containing either pETDuet-repA or pETDuet-1 and 100 pig/mL ampicillin were grown at 300C with
250 rpm shaking and induced with 0.5 mM IPTG at an OD600 of approximately 0.5. Six hours after
induction, 20-mL aliquots of culture were harvested by centrifugation. Lysates were prepared from the
pellets using disruption with 0.1 mm glass beads (Scientific Industries) in buffer containing 7 M urea, 0.1
M NaH 2PO4, and 0.01 M Tris-HCI at pH 8.0.
3.2.9 Plasmid quality assessment
Plasmid DNA purified from OD600 = 2 pellets using the Zyppy Plasmid Miniprep Kit (Zymo
Research Corporation; Irvine, CA) was run on a 0.7% agarose gel at 90 V for 60 min. to separate the
supercoiled, nicked (open-circle), and linear isoforms. The separated DNA was visualized by staining the
gel with 0.5 ig/mL ethidium bromide.
3.3 Results & Discussion
3.3.1 Characterization of plasmid yield
We constructed a new DNA vaccine vector, pDMB02-GFP, containing the runaway R1 replicon as
described in Section 3.2.1. The vector also carries the kanamycin resistance gene as well as the
sequences necessary for expression of therapeutic genes in a eukaryotic host. For this work, we have
included GFP as a placeholder for the therapeutic gene sequence. The specific yield of the new vector
was compared to that of both the parent vector (pCP40) and a pUC-based DNA vaccine vector (pVAXI-
GFP) after a mid-exponential phase temperature shift from 300C to 420C in LB medium (Figure 3-2). The
pUC-based vector behaved as expected - the specific yield remained low (less than 1 mg/g DCW) at
300C, and increased to about 4 mg/g DCW after temperature induction. Both of the Ri-based plasmids
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produced higher specific yields that the pUC-based plasmid. Interestingly, while temperature-induced
amplification was observed for the RI vectors at early time points (2 and 4 hours after the temperature
shift), at later time points the yield at 30"C was higher than or the same as that at 42*C. Note also that
the parent vector, pCP40, contains the phage lambda major leftward promoter (PL) upstream of the
origin (Appendix B, Figure B-1). Despite using a host (DH5a) that does not contain the PL repressor
protein, we did not observe the plasmid instability alluded to by Remaut et al. (1983). The completely
de-repressed phage promoter may not affect pCP40 stability because there is no recombinant protein
sequence immediately downstream of PL-
20
18 - I 2h 30*C 2h 420C
4h 30*C 4h 42*C









Figure 3-2. Specific yield of pCP40 (parent plasmid), pVAX1-GFP (pUC-based DNA vaccine vector), and pDMB02-
GFP (R1-based DNA vaccine vector) with and without a temperature shift from 300C to 420C. Times in the legend
are hours after the temperature shift.
To further investigate the production capabilities of pDMB02-GFP, the specific yield after a
temperature shift later in exponential phase (OD600 = 1) was compared to the yields obtained after a
mid-exponential phase shift (Figure 3-3). Typically, the temperature-shifted cultures reached a lower
final optical density than the cultures that remained at 30*C, likely due to heat stress (Figure 3-3A, 3-3B).
A period of increased growth rate was observed between 0 and 2 hours post shift - possibly due to the
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culture transiently being at optimal growth temperature for E. coli (37"C) - followed by growth arrest.
The timing of the temperature shift did not significantly impact the yield of the 420C cultures, but
resulted in higher yields at 30"C, likely due to the increased elapsed culture time. Also, the maximum
yield achieved in the experiments (Figure 3-3) was on par with the maximum yield produced by pCP40
(Figure 3-2), confirming that pDMB02-GFP did not lose any production capacity during the construction
process.
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Figure 3-3. (A) Growth of DH5a[pDMB02-GFP] with a temperature shift at OD600 = 0.5 and (B) OD 600 = 1.0. (C)
Specific yield of pDMB02-GFP with a temperature shift at OD 600 = 0.5 and (D) OD600 = 1.0. Data are shown for
cultures shifted to 42 0C (0) and cultures that remained at 30*C (A). 0 hr on the x-axis is the time of the
temperature shift.
There are several possible explanations for the experiment-to-experiment variability observed in
the maximum yield of pDMB02-GFP. The use of a rich medium (LB) may be partially responsible, as the
exact medium composition can vary from run-to-run. However, the mechanism of R1 replication is not
designed for tight control of plasmid copy number. Instead, the goal is to prevent the copy number
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from dropping below one per cell - a concern that is more relevant for the low-copy, wild-type R1
plasmid (Nordstrom, 2006). This may result in increased clone-to-clone variability when the plasmid
copy number is significantly higher than one, as observed in the runaway mutants.
3.3.2 Impact of seed growth phase on yield
In all of the experiments described above, shake flask cultures were inoculated directly from
working seed banks. However, it has been reported previously that the growth phase of the seed can
significantly impact the productivity of resulting cultures when using runaway replication plasmids for
recombinant protein production (Morino et al., 1988). To test the sensitivity of DH5a[pDMB02-GFP) to
seed age, we inoculated flasks using seeds in late exponential, early stationary, and late stationary phase
and measured the specific plasmid yield after 24 hours at 30*C. The data show that the plasmid
production capacity of DH5a[pDMB02-GFP] cultures inoculated using late-stationary seeds was greatly
reduced compared to cultures inoculated using seeds earlier in their respective growth phases (Figure 3-
4). In addition, the reduction in culture productivity corresponded to an increase in the plasmid content
of the seed culture, suggesting that high plasmid content in the seed negatively impacted the
productivity of resulting cultures. These results are consistent with the findings of a previous report
(Morino et al., 1988). Remaut et al. (1983) also alluded to the fact that runaway R1 plasmids can be
unstable after prolonged growth, even at low temperatures. Direct inoculation from the working seed
bank gave yields comparable to those obtained from late exponential/early stationary seeds, so we
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Figure 3-4. Specific yield of pDMBo2-GFP as a function of inoculum growth phase after 24 hours of culture at 30*C
in shake flasks (gray bars). The plasmid copy number of the seed cultures at each growth phase are also shown
(E). Specific yield error bars represent one standard deviation calculated from duplicate flasks, and copy number
error bars represent the 95% confidence interval calculated from three replicate wells of the same sample.
3.3.3 Quantification of repA gene expression
We were surprised to observe that pCP40 and pDMB02-GFP did not show the dramatic
temperature-induced amplification reported in the early literature characterizing the runaway Ri
replicon (Remaut et al., 1983; Uhlin et al., 1979). In particular, we expected greater copy number
control before the temperature shift; however, we are not the first group to observe that runaway
replication is not completely suppressed at 30*C (Mizutani et al., 1986; Morino et al., 1988). To further
investigate the temperature-dependent behavior of pDMB02-GFP we pursued additional studies at the
RNA and protein levels.
In the RI replicon, the repA gene codes for a protein required for initiation of replication at the
origin and is transcribed from both the PrepA and PeOpB promoters (Figure 3-5). copA is an antisense RNA
that binds to and inhibits translation of repA mRNA, and CopB is a tetrameric repressor of P,pA. The two
point mutations that lead to the runaway replication phenotype reduce the efficiency of PcopA and cause
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a temperature-dependent increase in transcription from Pcopa (Givskov et al., 1987). The replication
initiation protein, RepA, is likely the limiting factor in plasmid replication, owing to the fact that multiple
copies of the protein are required for initiation of replication (Nordstr6m, 2006). In the results that
follow, we chose to focus our analysis exclusively on repA. Our experiments were all in the high-copy-
number regime (compared to wild-type plasmid R1), and under these conditions, CopB is likely present
in sufficiently high amounts to completely repress PrepA such that all repA mRNA is transcribed from PcopB
(Light et al., 1985). Also, the antisense RNA control element, copA, is small and unstable (N6rdstrom
and Uhlin, 1992) and as such we were unable to obtain reliable measurements of its expression.
PcopA
Figure 3-5. Schematic of the R1 replicon.
The expression of repA was calculated relative to one of two replicate flasks at the time of the
temperature shift (t = 0 hr). As an internal standard, the same amount of total RNA was used for all
reverse transcriptase reactions in lieu of a housekeeping gene, since it is unlikely that transcription of a
chromosomal target would remain unchanged under all temperature and growth conditions tested.
Relative expression measurements of repA in cultures of pDMB02-GFP with and without a temperature
shift showed that repA transcription increased by an order of magnitude after the temperature shift
(Table 3-1). However, the pDNA specific yield did not increase in a similar manner, consistent with the
observations made in previous experiments. The repA expression data suggest that the runaway RI
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replicon is functioning as expected, in that there is clear temperature-induced expression of repA mRNA.
However, as the plasmid copy number increases, the total amount of repA mRNA in the culture is also
expected to increase. To account for this, we normalized repA expression to plasmid copy number to
obtain an estimate of the relative repA expression level per plasmid (Table 3-1) and found that
temperature-induced expression of repA was still evident.
Table 3-1. Specific yield, plasmid copy number, and repA expression from pDMB02-GFP with and without a
temperature shift. Error bars represent the standard deviation of duplicate samples.
Time Specific Yield Plasmid repA repA
Temperature (mg pDNA/ copies/ expression/(hr)a g DCW) chromosome expression plasmidd
0 NDb 42 ±2 1.07 ± 0.10 1.07 ±0.16
2 1.5 ± 0.1 90 ± 9 0.69 ± 0.02 0.32 ± 0.05
30"C
4 4.4 ± 0.2 144 t 3 0.77 ± 0.25 0.22 ± 0.08
8 7.0 ± 0.3 212 72 1.40 ± 1.74 0.27 ± 0.36
2 2.2 ± 0.0 153 3 12.50 ± 2.55 3.40 ± 0.78
420C 4 4.2 ± 0.1 105 39 28.15 ± 1.48 11.21 4.33
8 5.1 0.6 177 29 24.60 ± 0.14 5.78 1.12
aTime after temperature shiftbNot detected (below detection limit of HPLC assay)
cNormalized to repA expression at t = 0 in flask replicate 1
drepA expression multiplied by a factor of (t = 0 plasmid copy number)/(plasmid copy number of sample) to give an
estimate of normalized repA expression per plasmid
3.3.4 Role of RepA protein expression levels
The repA mRNA expression data pointed to the possibility of a post-transcriptional limitation on
plasmid yield at 420C. One possible option for relieving this limitation is to increase expression of RepA.
To this end, we changed the RepA start codon in pDMB02-GFP from GTG to ATG, resulting in the plasmid
pDMB-ATG. There is evidence in the literature that genes with a GTG start codon are typically translated
several-fold less efficiently than genes with an ATG start codon (Kozak, 2005). We chose a start codon
mutation instead of a promoter replacement to minimize disruption of the other elements of the
replicon. Also, since RepA is primarily cis acting (Masai and Arai, 1988), supplying RepA exogenously
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from either the chromosome or an additional plasmid was not a viable strategy for increasing RepA
availability.
In a mid-exponential phase temperature shift experiment, pDMB-ATG showed distinctly
different plasmid yield profiles compared to pDMB02-GFP (Table 3-2). The specific yield at 30*C was
lower than that typically observed for pDMB02-GFP, and there was an approximately five-fold increase
in specific yield after temperature induction. repA RNA expression also showed temperature-induced
amplification (Table 3-2); the fold difference between the 30*C and 42*C cultures containing pDMB-ATG
was approximately the same order of magnitude as that observed for pDMB02-GFP (Table 3-1).
However, when repA expression was normalized to plasmid copy number, temperature-induced
transcription of repA was still evident but to a lesser degree; the mechanism responsible for this
observation is unclear.
Table 3-2. Specific yield, plasmid copy number, and repA gene expression in cultures of DH5a[pDMB-ATG] with and
without a temperature shift. Error bars represent the standard deviation of duplicate samples.
Time Specific yield Plasmid repA repA
Temperature (mg pDNA/ copies/ c expression/(hr)a g DCW) chromosome expression plasmidd
0 NDb 13 ± 3 0.09 ± 0.01 0.30 ± 0.09
2 0.2 ± 0.1 20 ± 4 0.06 ± 0.00 0.13 ±0.03
30*C 4 1.0 ± 0.0 54 ±1 0.20 ±0.02 0.15 ±0.02
8 2.3 ± 0.3 96 27 0.32 ±0.02 0.14 ±0.04
2 1.9 ± 0.1 243 32 1.00 ± 0.08 0.17 ±0.03
420C 4 5.1 ± 1.9 407 ± 210 15.20 ± 1.13 1.56 ± 0.83
8 11.4 ± 1.7 476 ± 176 9.85 t 0.64 0.86 ± 0.34
"Time after temperature shift
bNot detected (below detection limit of HPLC assay)
"Normalized to repA expression from pDMB02-GFP at t = 0 in flask replicate 1 (Table 3-1)
drepA expression multiplied by a factor of (t = 0 pDMB02-GFP copy number)/(plasmid copy number of sample) to
give an estimate of relative repA expression per plasmid
To qualitatively evaluate the expression of RepA protein in cultures of DH5a[pDMB02-GFP] and
DH5a[pDMB-ATG] we used a Western blot to detect RepA using polyclonal antiserum obtained from
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rabbits. For pDMB02-GFP, a band corresponding to RepA (33 kDa) was visible on the blot after 2 hr at
42*C and after 8 hr at 30*C, with the intensity of the RepA band being higher in the 30*C lysate (Figure 3-
6: Lanes 6 and 7). This suggests that temperature-induced expression of RepA from pDMB02-GFP was
occurring two hours post-shift, but by 8 hours, protein was either no longer being translated or was
degraded, possibly by heat-shock-induced proteases (Gross, 1996). A higher molecular weight band is
visible in all lanes, but since this band is also present in the negative control lanes (Figure 3-6: Lanes 1
and 3), it is likely due to cross-reaction with either the primary or secondary antibody rather than
expression of RepA. As with specific plasmid yield, the trends in RepA expression were also different for
pDMB-ATG. A RepA band is visible in the lanes corresponding to the 42*C samples at both 2 and 8 hours
post-shift, and in the lane containing the 300C sample at 8 hours post-shift (Figure 3-6: Lanes 11-13).
The band for the 8 hr, 42*C sample is the most intense. It is clear that the kinetics of RepA expression
are different for pDMB-ATG, and that RepA expression persists longer after the temperature shift when
compared to expression from pDMB02-GFP.
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Figure 3-6. Western blot for RepA. The RepA band is indicated by the arrow to the right of the image. Except for
the lane containing the protein marker, all lanes contained crude lysates from the cultures indicated. Lane 1: BL21
Star (DE3) [pETDuet-1], Lane 2: BL21 Star (DE3) [pETDuet-repA], Lane 3: DH5a (no plasmid), Lane 4:
DH5a[pDMB02-GFP] t=O hr, Lane 5: DH5a[pDMB02-GFP] t=2 hr 300C, Lane 6: DH5a[pDMB02-GFP] t=2 hr 42*C,
Lane 7: DH5a[pDMB02-GFP] t=8 hr 30*C, Lane 8: DH5a[pDMB02-GFP] t=8 hr 42*C, Lane 9: DH5a[pDMB-ATGJ t=O
hr, Lane 10: DH5a[pDMB-ATG] t=2 hr 300C, Lane 11: DH5a[pDMB-ATG) t=2 hr 420C, Lane 12: DH5a[pDMB-ATG]
t=8 hr 30*C, Lane 13: DH5a[pDMB-ATG] t=8 hr 42*C, Lane 14: Protein marker. Times indicate hours after the
temperature shift. All lanes contained 2 pg total protein except for Lane 2, which contained 0.4 pg total protein.
Results are shown for a single set of flasks, but the same trends in RepA expression were observed for the second
replicate samples as well.
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Taken with the RNA expression data, the protein expression data for pDMB02-GFP suggest RepA
protein levels may be limiting replication at 42*C. While we cannot deconvolute whether more RepA
expression is leading to higher copy number or vice versa, it is clear that RepA protein is depleted after 8
hours at 42*C for the wild-type plasmid, and that the start codon mutation increases RepA protein levels
at this time point. Despite this limitation, we have shown that high yields of pDMB02-GFP can be
produced during constant-temperature growth at 30"C without a temperature shift. This is particularly
advantageous for production-scale runs, as it reduces the complexity of the process and allows the
culture to achieve a higher final cell density. In addition, the mutant plasmid pDMB-ATG seems to
perform better at 42"C, making it the more attractive vector if a process with a temperature shift is
desired.
3.3.5 Plasmid quality
For biopharmaceutical applications, it is important to assess the quality of the plasmid DNA
produced in addition to the yield. While there is some debate over the differences in immunogenicity of
the various plasmid isoforms (supercoiled, nicked, and linear), the FDA currently recommends that
plasmid DNA biopharmaceuticals contain predominantly the supercoiled isoform (Klinman et al., 2010).
Gel electrophoresis analysis of samples of pDMB02-GFP and pDMB-ATG collected from cultures with
and without a temperature shift show a high percentage of supercoiled DNA (Figure 3-7). Also, the
trends in plasmid quantity are consistent with the specific yield measured for these samples (Table 3-1
and Table 3-2).
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Figure 3-7. Agarose gel electrophoresis of pDMB02-GFP and pDMB-ATG produced in DH5a with and without a
mid-exponential phase temperature shift from 30*C to 42*C. Lane 1: DNA ladder with DNA size in kilobases (kb)
indicated to the left of the image, Lane 2: pDMB02-GFP t=2 hr 30*C, Lane 3: pDMB02-GFP t=2 hr 42*C, Lane 4:
pDMB02-GFP t=4 hr 300C, Lane 5: pDMB02-GFP t=4 hr 42*C, Lane 6: pDMB02-GFP t=8 hr 30*C, Lane 7: pDMB02-
GFP t=8 hr 420C, Lane 8: pDMB-ATG t=2 hr 300C, Lane 9: pDMB-ATG t=2 hr 42*C, Lane 10: pDMB-ATG t=4 hr 30*C,
Lane 11: pDMB-ATG t=4 hr 42 0C, Lane 12: pDMB-ATG t=8 hr 300C, Lane 13: pDMB-ATG t=8 hr 42 0C, Lane 14: DNA
ladder. Times indicate hours after the temperature shift.
These data show that neither the elevated temperature nor the start codon mutation had a
negative impact on plasmid quality. Thus, pDMB02-GFP and pDMB-ATG are capable of producing not
only high yields of plasmid DNA, but high quality product as well.
3.4 Conclusions
in this work, we have described construction of a new DNA vaccine vector, pDMB02-GFP,
containing the runaway R1 origin of replication. Our new vector produced high yields of high quality
plasmid DNA during constant-temperature culture at 30"C. The runaway R1 replicon has been reported
to result in a temperature-dependent loss of copy number control, with higher copy numbers at higher
temperatures. However, while we observed some temperature-induced amplification of pDMB02-GFP
shortly after a temperature shift, at longer times, the yield at 30'C was often higher than that at 420C.
Using RNA and protein expression measurements, we demonstrated that RepA protein availability may
be limiting pDMB02-GFP yield at 420C. To increase RepA protein levels, we constructed a second vector,
pDMB-ATG, in which the start codon of repA was changed from the sub-optimal GTG to ATG. RepA was
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detected in cultures of DH5ct[pDMB-ATG] up to 8 hours after a temperature shift and was accompanied
by enhanced temperature-dependent plasmid amplification.
Overall, we have developed a new set of high-yielding DNA vaccine vectors that are well suited
to processes run at low temperatures (pDMB02-GFP) as well as processes that include a temperature
shift (pDMB-ATG). Future work to systematically vary the expression of RepA and to determine the
resulting effects on specific yield will guide additional efforts to maximize plasmid production.
Furthermore, the mechanistic insight into the factors limiting R1 replication gained in this work can




Scale up of R1-based vector production
Abstract
The recent renewed interest in plasmid-based biopharmaceuticals has led to an increased
demand for high-yield, economic processes for plasmid DNA (pDNA) production. At the bioreactor
scale, plasmid DNA is typically produced in E. coli using a fed-batch fermentation strategy. Successful
scale up requires leveraging both an understanding of plasmid and host physiology as well as systematic
investigation of process parameters. In this work, we have scaled up production of a DNA vaccine vector
containing the runaway R1 replicon, pDMB02-GFP, from 50-mL shake flasks to 2-L bioreactors in E. coli
DH5a. Based on results in shake flasks, we chose to cultivate DH5a[pDMB02-GFP] at a constant
temperature of 30*C. We modified an existing culture medium with respect to carbon source,
hydrolysate source, and concentration of MgSO 4-7H20. Using this medium at the 2-L-scale, we found
that high growth rates were correlated to low plasmid specific yields. To remedy this, we implemented
a growth rate control strategy by reducing dissolved oxygen levels and were able to produce 5.1 mg/g
DCW of pDMB02-GFP. Overall, this work has led to an understanding of some of the key aspects of
successful scale up of Ri-based vector production.
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4.1 Introduction
As discussed in previous chapters, there has recently been increased interest in plasmid-based
DNA vaccines and gene therapies. With this interest comes increased demand for high-yield,
economical processes for the production of high-quality plasmid DNA (pDNA). In an industrial setting,
the vector and host are typically defined before scale-up studies begin; however, there are still many
scale-up decisions that can significantly impact process productivity.
Plasmid DNA is often produced in a fed-batch process to allow for controlled accumulation of
high cell densities. Depending on the replicon, a temperature shift may be used to induce plasmid
amplification after sufficient biomass is produced. In fed-batch processes, substrate is typically added at
a constant rate or using an exponential algorithm that allows control of growth rate at a constant value;
the latter strategy often results in higher productivity (Carnes et al., 2006). Fed-batch fermentations
have also been shown to result in an increase in the content of supercoiled plasmid over batch
fermentations, possibly due to lower growth rate and reduced exposure to stationary-phase growth
conditions (O'Kennedy et al., 2003). While many of the high-yielding plasmid production processes in
the literature use fed-batch fermentations (Carnes et al., 2006; Danquah and Forde, 2008; Listner et al.,
2006b; Williams et al., 2009b), there has been some investigation of high cell density batch processes for
plasmid production (Soto et al., 2011).
Process scale can also impact strain physiology and gene expression; facts that are particularly
evident in reports comparing genetic engineering strategies across scales. For instance, Ow et al. (2009)
observed that knocking out the global regulatorfruR in E. coli DH5a only resulted in improved plasmid
specific yield in an exponential fed-batch culture, not a batch cultivation. Also, Williams et al. (2009b)
saw that the impact on plasmid yield of overexpressing DNA replication enzymes or primosomal
components varied significantly between batch test-tube scale and fed-batch fermenter scale cultures;
in some cases, a mutation was detrimental at one scale and favorable at another.
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An additional aspect of plasmid production that is often considered during scale-up studies is
medium design. O'Kennedy et al. (2000) found that using a semi-defined versus a rich medium in shake
flasks reduced genomic DNA contamination of alkaline lysates, and that modulating the C:N ratio could
induce 10-fold changes in plasmid specific yield. Other shake flask studies systematically investigated
different carbon and nitrogen sources and quantified their effects on volumetric and specific yields (Xu
et al., 2005; Zheng et al., 2007). A medium has been designed specifically for plasmid DNA production
using a stoichiometric model (Wang et al., 2001). A modified version of this medium with an optimized
C:N ratio that also excluded expensive nucleosides and amino acids has been used for high-yield
production of pUC-based DNA vaccine vectors in fed-batch, pilot-scale cultures (Danquah and Forde,
2008).
While all of the studies discussed above used ColEl-based plasmids they still may be able to
inform design of a bioreactor-scale process for Ri-based vector production. There are many reports in
the literature of process development for R1 vectors (Ansorge and Kula, 2000; Hoffmann et al., 1987;
Kidwell et al., 1996; Morino et al., 1988), but the goal of these reports was to maximize recombinant
protein production, and the process parameters required to maximize plasmid production may be
significantly different.
In this chapter, we demonstrate scale up of production of DH5a[pDMB02-GFP] from 50-mL
shake flask cultures to 2-L bioreactors in a semi-defined medium at 300C. We report our modifications
to the medium described by Listner et al. (2006a) with respect to carbon source, hydrolysate source, and
MgSO 4-7H20 concentration. Despite initial low yields in fed-batch and batch cultures, we were
ultimately able to produce 5.1 mg/g DCW of pDMB02-GFP using a growth rate control strategy during
batch fermentation.
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4.2 Materials and Methods
4.2.1 Plasmid and strain
This study used E. coli DH5a [F~ <b80/acZAM15 A(lacZYA-argF)U169 deoR recAl endAl hsdRl7(rk-,
mk') phoA supE44 thi-1 gyrA96 re/Al K] as a host for the plasmid pDMB02-GFP (5668 bp). The
construction and features of pDMB02-GFP are described in detail in Section 3.2.1.
4.2.2 Preparation of working seed banks
Frozen working seed banks of DH5a[pDMB02-GFP] were prepared by transforming subcloning-
efficiency, chemically-competent DH5a (Invitrogen; Carlsbad, CA) with purified plasmid. Positive
transformants were selected on LB/agar plates containing 25 pg/mL kanamycin. After overnight
incubation at 30*C, a single colony was used to inoculate 3 mL of LB medium containing 25 ptg/mL
kanamycin. The culture was incubated overnight at 30*C. The next day, 500 pL of overnight culture was
used to inoculate 50 mL of LB medium containing 25 pg/mL kanamycin in a 250-mL shake flask. The
culture was incubated at 30 0C until mid-exponential phase (OD600 approximately equal to 0.5), at which
time 900 pL of culture was added to 900 pL of cold 30% (v/v) glycerol in a cryogenic vial and immediately
stored at -80 0C. Working seed bank vials were discarded after two freeze-thaw cycles.
4.2.3 Culture medium
A semi-defined culture medium was adapted from Listner et al. (2006a). The basal medium
contained 3 g/L (NH4 )2SO 4 , 3.5 g/L K2HPO 4, 3.5 g/L KH2PO4, 10 g/L yeast extract, and 10 g/L Bacto
peptone (BD; Franklin Lakes, NJ). Difco Select Soytone (BD) was used in place of Bacto peptone for some
cultures as part of the medium development experiment described in the text. 8.3 mL/L seed
supplement solution, 1 mL/L trace elements solution, and 25 pg/mL kanamycin were added as
supplements to the basal medium. Unless otherwise noted, 5 g/L glycerol was added to the medium as
78
well. The seed supplement solution typically contained 60 g/L MgSO 4 -7H20 and 24 g/L thiamine
hydrochloride, except in experiments that systematically varied the concentration of MgSO 4-7H2 0 as
described in the text. The trace elements solution contained 16.2 g/L FeCl 3, 2 g/L ZnC 2, 2 g/L
CoCl 2-6H20, 2 g/L Na2MoO4-2H 20, 1 g/L CaCI2*2H 20, 1.27 g/L CuCl 2 2H20, and 0.5 g/L H3B03 dissolved in
1.2 N hydrochloric acid. The pH of the basal medium was adjusted to 7.1 using NaOH.
4.2.4 Shake flask cultures
For medium development purposes, shake flask cultures were prepared using various
combinations of hydrolysate source and MgSO 4-7H20 concentration (Table 4-1). All other components
of the semi-defined medium were as described in Section 4.2.3. Cultures were mixed and aerated by
agitation at 250 rpm unless stated otherwise.









3-mL seed cultures containing each medium composition (Table 4-1) were inoculated with 0.4%
DH5a[pDMB02-GFP] working seed bank. A culture prepared in LB medium was also included, and all
seed cultures contained 25 pg/mL kanamycin. Seed cultures were incubated overnight at 30*C. The
next day, 50-mL shake flask cultures containing each of the medium compositions were inoculated in
duplicate to an initial OD600 = 0.03 with seed cultures that were in late-exponential or early-stationary
growth phase. Cultures were incubated at 300C for a total of 24 hours. After 10 hours of incubation, a
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bolus of glycerol was added to each culture (with the exception of the LB cultures) to a final
concentration of 5 g/L.
In a separate experiment, shake flask cultures were run using the final medium composition
(Section 4.2.3). For these cultures, the seed was prepared by inoculating 5 mL of semi-defined medium
(including 5 g/L glycerol) with 0.4% DH5a[pDMB02-GFP] working seed bank and incubating the culture
overnight at 30'C. All other cultures conditions were the same as those described above, except no
additional glycerol was added to the cultures.
4.2.5 Fed-batch bioreactor cultures
Fed-batch bioreactor cultures were performed using a Labfors 3 bioreactor (Infors; Bottmingen,
Switzerland) with a 5.0 L maximum working volume. The bioreactor was equipped with a D140
OxyProbe dissolved oxygen sensor (Broadley-James; Irvine, CA) and an F-695 FermProbe pH electrode
(Broadley-James). To prepare the bioreactor inoculum, 3 mL of semi-defined medium was inoculated
with 0.4% seed bank and grown overnight at 30 0C. The next day, two cultures, each containing 100 mL
of semi-defined medium, were inoculated with 1 mL of overnight culture in a 500-mL baffled shake flask
and incubated overnight at 30"C. 3.5 L of basal cultivation medium were autoclaved in the reactor.
On the day of inoculation, medium supplements (including 5 g/L glycerol) and 0.2 mL Antifoam
204 (Sigma-Aldrich; St. Louis, MO) were added, and the reactor was inoculated to an initial OD600 of 0.05
using the overnight seed cultures. The reactor was run in batch mode at 300C until all of the batched
glycerol was consumed, as evidenced by a sudden increase in dissolved oxygen. At this time, feeding of
a solution containing 321.4 g/L glycerol and 79.3 g/L yeast extract began at a flow rate of 0.54 mL/min.
The entire run time was 30 hours.
Dissolved oxygen was controlled at 35% using a cascade to agitation (400 rpm to 850 rpm), and
air was provided at a flow rate of 0.7-0.9 vvm. pH was controlled at 7.10 ± 0.05 using 4 M NaOH and
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2.25 M H3PO4. Antifoam was manually added in 0.2-mL increments as needed. Online data was logged
using IRIS fermenter log and control software (Infors). Samples were taken periodically to measure
OD600 offline using a DU800 Spectrophotometer (Beckman Coulter; Indianapolis, IN). Samples for
glycerol, acetate, and plasmid DNA concentration measurements were stored at -30*C until analysis.
4.2.6 Batch bioreactor cultures
Batch bioreactor cultures were performed using a Labfors 3 bioreactor (Infors) with a 2.3 L
maximum working volume. The bioreactor was equipped with a D140 OxyProbe dissolved oxygen
sensor (Broadley-James) and an F-695 FermProbe pH electrode (Broadley-James). To prepare the
bioreactor inoculum, 3 mL of semi-defined medium was inoculated with 0.4% seed bank and grown
overnight at 30 0C. The next day, 100 mL of semi-defined medium was inoculated with 1 mL of overnight
culture in a 500-mL baffled shake flask and incubated overnight at 30 0C. 2.0 L of basal cultivation
medium were autoclaved in the reactor.
On the day of inoculation, medium supplements (including 5 g/L glycerol) and 0.2 mL Antifoam
204 (Sigma-Aldrich) were added, and the reactor was inoculated to an initial OD600 of 0.03 using
overnight seed culture. The reactor was run in batch mode at 300C. Dissolved oxygen was controlled at
various setpoints, as described in the text, using a cascade to agitation (250 rpm to 850 rpm), and air
was provided at a flow rate of 1 vvm. pH was controlled at 7.10 ± 0.05 using 4 M NaOH and 2.25 M
H3PO4 . Data logging, OD600 measurements, and sample storage were performed as described in Section
4.2.5.
4.2.7 Measurement of glycerol and acetate concentrations
Glycerol and acetate concentrations in culture supernatants were determined using an Agilent
1200 Series HPLC (Agilent Technologies; Santa Clara, CA) equipped with an Aminex HPX-87H column
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(Bio-Rad; Hercules, CA). A 5 mM sulfuric acid mobile phase was run at 0.6 mL/min for 25 minutes at
50*C. Glycerol and acetate peaks were detected by refractive index at approximate retention times of
13.4 and 15.2 minutes, respectively.
4.2.8 Measurement of plasmid DNA specific yield
Plasmid DNA was quantified from crude lysates prepared from OD600 = 10 cell pellets using the
method described by Listner et al. (2006a). The lysis method was modified slightly: cell pellets were
harvested by centrifugation at 5000 x g for 15 minutes, the 370C incubation took place with 250 rpm
shaking, and 5 lpL of 10 mg/mL RNase A solution was used per mL of lysate. The pDNA content of the
lysates was measured using a Gen-Pak FAX anion-exchange column (Waters Corporation; Milford, MA)
on an Agilent 1100 Series HPLC system (Agilent Technologies). Three buffers were used: Buffer A (25
mM Tris-HCI, 1 mM EDTA, pH 8.0), Buffer B (25 mM Tris-HCI, 1 mM EDTA, 1 M NaCl, pH 8.0), and Buffer
C (0.04 M H3PO4). The LC method was run at a constant flow rate of 0.75 mL/min and consisted of the
following steps: (1) linear ramp from 70%:30% A:B to 34%:66% A:B over 10 min., (2) 100% B for 5 min.,
(3) 100% C for 4.5 min., and (4) 70%:30% A:B for 10 min. Plasmid DNA eluted at a retention time of
approximately 11.5 min as detected by absorbance at 260 nm. A standard curve of pVAX1-GFP (2 pg/mL
to 50 pg/mL) was prepared using pDNA purified using the Hi-Speed QlAfilter Plasmid Maxi Kit (Qiagen;
Valencia, CA) and quantified using a NanoPhotometer (Implen; Westlake Village, CA). The standard
curve was used to calculate the pg of pDNA per mL of lysate prepared from each pellet. Specific yield
was calculated using the correlation that 1 OD600 unit = 0.4 g DCW/L culture.
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4.3 Results and Discussion
4.3.1 Process medium design
To scale up production of the Ri-based DNA vaccine vectors from the shake flask to bioreactor
scale, we began by choosing a culture medium better suited to a high-density fed-batch process than LB.
After reviewing the literature, we chose to work with the semi-defined medium described by Listner et
al. (2006a) While a comprehensive medium optimization study was beyond the scope of this project,
several alterations were made to the published medium formulation to improve its performance in our
applications. Glycerol was used instead of glucose as the primary carbon source, as glycerol is often the
substrate of choice for plasmid DNA production due to a recent increase in availability as well as the
potential for reduced acetate secretion. To make our work as industrially-relevant as possible, we
aimed to replace the Bacto peptone used in our laboratory with a non-animal-derived soy hydrolysate,
specifically, Difco Select Soytone (BD). Another aspect of medium development that we pursued was
varying the concentration of MgSO4 -7H2 0 to prevent formation of a precipitate that was often observed.
This precipitate did not appear to impact cell growth, but was troublesome in micro-scale bioreactor
experiments (Chapter 2) as precipitate particles often blocked the optical sensors and interfered with
measurements. After calculating the amount of magnesium and sulfur required to achieve the cell
densities typically obtained in the bioreactors, we determined that the magnesium concentration could
be reduced at least four-fold without depriving the cells of required elements.
To test the re-designed medium, shake flask cultures of DH5a[pDMB02-GFP] were run in both
the Bacto- and soy-based media along with LB. MgSO 4-7H20 was included at concentrations of 2 g/L -
the concentration cited in Listner et al. (2006a), 1 g/L, and 0.5 g/L. The semi-defined medium was
supplemented with 5 g/L glycerol, while the LB contained no additional carbon source. We did not
observe any significant differences in the growth curves between the Bacto- and soy-based media
(Figure 4-1A). However, the cultures containing Select Soytone attained a slightly higher cell density by
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the 9.5-hr time point. The final cell densities of cultures in both semi-defined media were comparable,
and significantly higher than the cultures grown in LB due to the presence of glycerol as an additional
carbon source (Figure 4-1B). Reducing the concentration of MgSO 4-7H20 to 0.5 g/L did not significantly
impact growth rate or final cell density.
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Figure 4-1. (A) Growth curves and (B) final OD600 (cell density after 24 hours of incubation at 30*C) for cultures of
DH5a[pDMB02-GFP] in semi-defined medium containing either Bacto or soy peptone along with varying
concentrations of MgSO4-7H20 in shake flasks. Growth of cultures in LB medium with no glycerol is also shown.
OD600 values are reported as the average of two replicates. For (A), the standard deviations are not shown
because all were less than 0.13 OD600 units. The error bars in (B) represent one standard deviation.
The maximum plasmid yield was about the same for both peptones, but the kinetics of plasmid
accumulation differed somewhat (Figure 4-2). This was especially evident at 6.5 hours when there was
no detectable plasmid in the soy peptone cultures, while the Bacto peptone cultures contained about 2
mg pDNA/g DCW. Reducing the concentration of MgSO4 -7H20 to 0.5 g/L did not impact plasmid yield
and prevented precipitate formation. Interestingly, the plasmid yields in semi-defined media were
similar to those in LB, suggesting that the presence of a carbon source in addition to those found in the
rich medium components didn't increase plasmid yields. However, the glycerol-supplemented cultures
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Figure 4-2. Specific yield of pDMB02-GFP in semi-defined medium containing either Bacto or soy peptone along
with varying concentrations of MgSO4 7H 20 in shake flask scale culture. LB medium with no glycerol was also
included. Cultures were grown at 30*C for 24 hours; the flasks containing semi-defined medium were
supplemented with 5 g/L glycerol at the start of the experiment and 10 hours after inoculation. Error bars
represent one standard deviation calculated from two replicate cultures.
While the maximum plasmid yield was about the same for both peptones, there were some
differences in the glycerol utilization and acetate production profiles of the Bacto and soy peptones
(Table 4-2). Despite nearly identical growth curves, cultures containing soy peptone consumed glycerol
more slowly and produced more acetate than those containing Bacto peptone. These differences may
be due to the fact that soy peptones have a significantly higher concentration of carbohydrates than
Bacto peptones (336.2 mg/g vs. 6.29 mg/g; (BD Biosciences, 2006)); these carbohydrates have not been
further characterized by the manufacturer beyond their total concentration.
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Table 4-2. Glycerol and acetate concentrations measured in the supernatants of cultures containing either Bacto or
soy peptones and various concentrations of MgSO 4-7H 20
Peptone [MgSO4-7H20] Glycerol (g/L) Acetate (g/L)
(g/L) 9.5 hr 24 hr 9.5 hr 24 hr
2 3.5 0 0.2 0
Bacto 1 3.4 0 0.2 0
0.5 3.7 0 0.2 0
2 4.0 0.3 0.7 0.6
Soy 1 3.7 1.1 0.8 0.2
0.5 3.7 2.3 0.8 0.3
After evaluating the results shown above, we decided to proceed with the medium containing
Bacto peptone to avoid the potential for increased acetate production and to ensure that the higher
carbohydrate content of the soy-based medium would not interfere with glycerol feeding strategies
pursued at the bench scale.
4.3.2 Scale up challenges
Based on the high yields of pDMB02-GFP observed during constant-temperature culture at 30*C
in shake flasks, we chose to pursue a constant-temperature process at the bench scale as well.
However, challenges were encountered during scale-up. In particular, we observed that DH5a[pDMB02-
GFP] grew at a faster rate and produced significantly less plasmid DNA at the bench scale. In a fed-batch
fermentation at 300C with an initial specific feed rate of approximately 3 g glycerol/L/hr there was a 1.7-
fold increase in growth rate accompanied by a 20-fold decrease in specific pDNA yield compared to
batch shake flask cultures (Table 4-3). Feeding at 3 g glycerol/L/hr resulted in high oxygen demand, and
as such, the DO setpoint of 35% could not be maintained after the start of feeding.
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Table 4-3. Summary of maximum values of specific growth rate (pmax), doubling time (tD), OD600, specific yield, and
volumetric yield observed under various culture conditions at shake flask and bioreactor scales.
p1max tD Max Max sp. yield Max vol. yield
(hr 1 ) (hr) OD600  (mg/g DCW) (mg/L)
Shake flask (batch) 0.33 2.1 8.8 14.2 50.3
Fed-batch 0.56 1.2 57.7 0.7 13.0
Batch (35% DO) 0.49 1.4 13.5 0.8 3.6
Batch (10% DO) 0.56 1.2 15.3 0.3 0.7
Since the conditions encountered in shake flasks clearly facilitated plasmid production, we ran
several batch fermentations to attempt to replicate these conditions. 2-L batch cultures were run with
dissolved oxygen setpoints of 35% and 10%. The lower setpoint was investigated in order to better
replicate the conditions in shake flasks, where oxygen transfer is likely slower than that achieved in the
stirred-tank vessels. Neither condition resulted in improved specific yield; increased growth rate
compared to shake flask cultures was still observed (Table 4-3).
4.3.3 Batch bioreactor with growth rate control
For the bioreactor experiments described above, we cannot definitively determine whether the
faster growth rate caused the lower yield, or vice versa. However, there is evidence in the literature
that slower growth rates may favor increased plasmid production, both for pMB1/ColE1 (Lin-Chao and
Bremer, 1986; Seo and Bailey, 1985) and R1 plasmids (Engberg and Nordstrom, 1975; Siegel and Ryu,
1985). With this in mind, we pursued a strategy to control the growth rate by limiting dissolved oxygen
availability, rather than allowing the cultures to grow unrestricted until glycerol was exhausted, as was
the case in the experiments described above. To achieve this, we began a batch fermentation by only
aerating the culture via air sparging, then slowly increased the agitation as the cell density increased.
The culture grew at maximum growth rate for approximately the first 5 hours of culture, after which we
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Figure 4-3. Dissolved oxygen (gray line) and growth (0) profiles from a batch culture of DH5a[pDMB02-GFP]. The
agitation rate was increased gradually throughout the run as indicated at the top of the figure.
This growth rate control strategy resulted in a marked increase in specific and volumetric yields
of pDMB02-GFP compared to the values observed in batch cultures with un-restricted growth rate
(Figure 4-4). The specific yield peaked after 26.5 hours, reaching a maximum value of 5.1 mg/g DCW,
while the volumetric yield peaked later in the culture after the additional biomass accumulation that
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Although the specific yield obtained in the growth-rate-controlled batch run was lower than that
observed in shake flasks (Table 4-3) it was on par with yields observed previously for DH5a[pDMB02-
GFP] under suboptimal conditions (Section 3.3.1). Thus, growth rate control is a viable strategy for
maintaining the productivity of Ri-based DNA vaccine vectors during scale up. As part of future work in
this area, growth rate control via exponential, substrate-limited feeding may allow for both increased
plasmid yield and higher biomass accumulation. These experiments may also provide insight into
whether reduced growth rate or low dissolved oxygen is the true cause of increased specific yield. In
addition, we have found that Ri-based plasmids are sensitive to the growth phase of seed cultures;
specifically that late stationary phase seeds can result in reduced culture productivity (Section 3.3.2).
With this in mind, optimization of the seed train used for the bioreactor-scale studies is also a promising
strategy for improving plasmid production.
4.4 Conclusions
In this chapter, we have demonstrated scale up of production of the Ri-based DNA vaccine
vector, pDMB02-GFP, from the shake flask (50 mL) to bioreactor (2 L) scale. Based on results in shake
flasks, we chose to run all cultures at a constant 300C. All scale up experiments used E. coli DH5a as the
host strain, and a semi-defined medium with glycerol as the primary carbon source. Initially, we
observed that the growth rate increased by an average of 1.6-fold on scale up. This growth rate
increase was accompanied by a 24-fold decrease in specific yield, on average, compared to shake flask
cultures. By controlling the growth rate using reduced dissolved oxygen levels we were able to improve
the specific yield to 5.1 mg/g DCW. While this is still lower than the specific yields typically observed in
shake flasks, it represents an approximately 9-fold improvement over our initial scale up experiments.
Future work in this area aims to leverage the knowledge gained during process development of a pUC-
based DNA vaccine vector (Chapter 2) and the molecular-level insights gained during characterization of
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To conclude my thesis, I have summarized the major findings of each chapter. I have also
included a discussion of recommendations for future work.
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5.1 Summary
The growing interest in plasmid-based DNA vaccines and gene therapies brings with it the need
for high-yield, rationally-designed pDNA production processes. In this thesis, I sought to meet this need
in several ways, as described below.
" In Chapter 2, my collaborators and I developed a 1-mL fed-batch microbioreactor device
capable of online monitoring and control of dissolved oxygen, pH, and temperature, as well
as continuous monitoring of cell density. We used the micro-device to scale down
production of a pUC-based DNA vaccine vector (pVAX1-GFP) and demonstrate the utility of
the device as a process design tool. We showed that plasmid copy number as well as
glycerol and acetate profiles were comparable across scales as long as key process
parameters such as dissolved oxygen were held constant. We also discovered that
conditions of high acetate and low dissolved oxygen may favor increased pVAX1-GFP copy
number.
" In Chapter 3, I constructed a new DNA vaccine vector containing the runaway R1 replicon.
The runaway mutant of the R1 replicon contains mutations that confer the phenotype of
increased plasmid copy number at high temperature (42*C). However, my runaway R1-
based DNA vaccine vector, pDMB02-GFP, produced the highest specific yields
(approximately 19 mg pDNA/g DCW) during constant-temperature culture at 300C. Analysis
of RNA and protein levels of the RI replication initiation protein, RepA, showed that a
temperature shift from 300C to 420C induced expression of repA mRNA, as expected from
the published mechanism of R1 replication. However, RepA protein was not detectable by
Western blot after 8 hours at 42"C, suggesting a protein limitation on plasmid yield. I
constructed a second DNA vaccine vector, pDMB-ATG, by mutating the RepA start codon
from GTG to ATG. The mutant plasmid showed lower plasmid yields at 30 0C and higher
plasmid yields at 420C compared to pDMB02-GFP, accompanied by detectable RepA protein
after 8 hours at 420C.
* In Chapter 4, I investigated the scale up of pDMB02-GFP production in E. coli DH5a from
shake flasks (50 mL) to bioreactors (2 L). First, I developed a semi-defined medium by
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evaluating both animal- and plant-derived hydrolysates. I found that hydrolysate source did
not significantly impact growth rate or final cell density, but ultimately decided to use
animal-derived Bacto peptone because it contained lower concentrations of carbohydrates
and resulted in less acetate production. Initial scale up efforts using both fed-batch and
batch strategies at 300C resulted in a 24-fold decrease in specific yield accompanied by a
1.6-fold increase in specific growth rate compared to shake flasks. In a subsequent batch
fermentation, I controlled the growth rate at roughly 0.1 hr 1 by modulating agitation to
reduce the dissolved oxygen concentration. This resulted in a maximum pDMB02-GFP
specific yield of 5.1 mg/g DCW - a significant improvement over the initial scale up
experiments.
5.2 Recommendations for future work
Ph.D. thesis research is never truly finished. There are endless ways to refine and extend the
research conducted during a thesis project. Here, I outline several proposed directions for future work
in developing new tools for the production of plasmid DNA biopharmaceuticals.
In Chapter 2, my colleagues and I demonstrated that 1-mL fed-batch microbioreactors can
effectively reproduce a bench-scale, temperature-induced pDNA production process. The microreactors
are inexpensive to fabricate and operate and can be disposed after a single use. However, to truly
harness the high-throughput power of micro-scale devices the next step in this work must be to
multiplex the devices so that many cultures can be run in parallel under varying conditions. This work is
being actively pursued by Pharyx, Inc. (www.pharyx.com), a start-up company from Prof. Rajeev Ram's
laboratory at MIT. As the microreactor technology continues to mature, a more refined and robust user
interface will increase their usefulness as well.
Another aspect of micro-scale bioprocessing that should be pursued in the future is the
development of companion, micro-scale analytics. I developed a qPCR assay to measure plasmid copy
number from pL-scale culture volumes, but this analysis was still limited by the frequency of sampling,
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i.e. collection of too many samples could lead to significant changes in the culture volume. Analytics
that provide online analysis of metabolites and product concentrations would be an ideal complement
to micro-scale technology. In one promising area of work, Zanzotto et al. (2006) investigated the use of
luminescent and fluorescent reporters for online monitoring of gene expression, and found that the high
surface area to volume ratio of microscale devices makes them well suited to this type of analysis.
Finally, there has also been recent work on designing scaled-down versions of downstream purification
trains (Titchener-Hooker et al., 2008) which may eventually allow scale down of both the upstream and
downstream stages of a bioprocess. Scale down of the complete process can facilitate high-throughput
analysis of the impact of process conditions on the final product.
In Chapter 3, I described construction and characterization of new DNA vaccine vectors
containing the runaway R1 origin of replication. One potential area of future work is design of a strain
specifically suited to production of these vectors. It has been shown in the literature that host strain can
significantly impact plasmid yield (Yau et al., 2008), and my own preliminary data have shown that Ri
plasmid yield varies with host strain. In addition, current plasmid production processes result in yields
that are much lower than the theoretical maximum, and it has been shown that strain engineering may
be able to close this gap (Appendix A). To remove confounding strain effects from my analyses of R1
replication, I chose to use E. coli DH5ct exclusively in this thesis. DH5a is commonly used for plasmid
production at the bioreactor scale, but recent work in our laboratory suggests that de novo construction
of strains specifically suited for plasmid production (using wild-type E. coli MG1655 as the parent strain)
can increase plasmid yields (Gongalves GAL et al., in preparation). The strain engineering work by
Gongalves et al. focused on engineering metabolism to redirect flux toward plasmid DNA intermediates.
Future strain engineering work could start with transcriptomic or flux analysis of strains carrying R1
plasmids to identify additional targets for beneficial flux redirection.
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Another potential way to improve the Ri-based DNA vaccine vectors designed in this thesis
would be to reduce their size. The R1 origin of replication and associated regulatory elements are larger
than the pUC origin (approximately 2.5 kb versus 0.7 kb, respectively). Smaller vectors are desirable
both because vector size may limit maximum titer and because smaller vectors typically give higher
transgene expression (Kay et al., 2010). R1 vector size could be reduced by production of minicircles or
use of a selection system that does not require a plasmid-based sequence (see discussion in Section
1.1.3). Minicircles are especially promising - a recent report on an improved method for minicircle
production and isolation suggests that these small vectors may soon be a viable (and desirable)
alternative to pDNA containing bacterial sequences (Kay et al., 2010).
Chapter 4 discussed scale up of Ri-based vector production and the associated challenges.
Future work in this area can leverage the knowledge gained during the microbioreactor studies. As
shown in Chapter 2, microbioreactors can accurately replicate a bench-scale pDNA production process
at the 1-mL scale and can also provide additional process insight. This insight, combined with
multiplexed microreactors, could provide a very useful platform for analysis of Ri-based plasmid
production. From the results presented in Chapter 4, it seems that growth rate and possibly dissolved
oxygen are key parameters in R1 vector production. Multiple microreactors run in parallel would be a
very effective method to evaluate the impact of these process parameters on plasmid copy number.
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Appendix A
Theoretical yield of plasmid DNA
As increasingly higher yields of plasmid DNA are produced, it is important to understand
whether or not the reported yields are approaching a theoretical maximum or if there is room for
further improvement. A recent article by Cunningham et al. (2009) used metabolic flux analysis to
estimate the maximum theoretical yield of a 3.3 kb plasmid in E. coli. They found that the optimal
conditions for plasmid DNA production were zero pyruvate kinase (Pyk) flux, no antibiotic resistance
marker production, no acetate production, and expression of a nicotinamide nucleotide
transhydrogenase to produce NADPH from NADH. Under these conditions, the predicted yield of
plasmid DNA was 592 mg/g dry cell weight. The highest specific yield reported in the literature is 51
mg/g DCW (Williams et al., 2009b), and values on this order were predicted by the Cunningham model
when fluxes representative of plasm id-bea ring E. coli JM101 were used. Hence, it may be possible to
achieve a 10-fold improvement in specific yield using metabolic and genetic engineering strategies.
However, there may be a limitation in the amount of physical space available to plasmid DNA in
the cell at the high theoretical yields predicted by the Cunningham model. We calculated the
approximate cellular volume occupied by 592 mg/g dry cell weight using estimates of E. coli cell volume
and chromosome size. The volume of the E. coli cytoplasm (Veco) fluctuates with medium osmolality,
but at 0.28 osm (near optimal value for E. coli growth) Ve 0o has been estimated to be 6.3 x 10-10 lpL per
cell (Cayley et al., 1991). About 1% of this volume is occupied by DNA in cells without plasmid
(Sundararaj et al., 2004), so the volume occupied by the genome(s) is approximately:
VDNA =O.Ox =O.01x6.3xl1010pL=6.3x10-12pL
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The number of chromosomes in an E. coli cell varies considerably with growth rate and phase, but for
this analysis we assumed two chromosomes per cell. The volume occupied by a DNA base pair in the
cell was calculated by dividing VgDNA by the number of basepairs (n) in two E. coli chromosomes:
Volume VgDNA 6.3xl - 1 pL =6.72x101 9 ,pL
bp 2n 2(4.69x106bp) bp
The maximum specific yield of 592 mg/g reported by Cunningham et al. (2009) corresponds to
about 48,500 copies/cell or 1.60 x 108 bp/cell using the conversion factors of 3.0 x 1013 g dry weight per
cell (Neidhardt and Umbarger, 1996), a basepair molecular weight of 660 g/mol, and the plasmid size of
3337 bp. Combining this copy number with the volume/bp calculation shown above, the volume
occupied by the plasmids is about 1.08 x 1010 pL. This corresponds to about 17% of the cytoplasmic
volume of the cell. Since 70% of a plasmid-free E. coli cytoplasm is occupied by water (Neidhardt and
Umbarger, 1996), it could be argued that occupying 17% of the cytoplasm with pDNA would not be
detrimental enough to the cell to limit pDNA production. Occupation of cytoplasmic volume by pDNA
would, however, reduce the free volume of water in the cell due to an increase in bound water via








Figure B-1: Plasmid feature maps. pVAX1-GFP is a pUC-based DNA vaccine vector used in the microbioreactor
studies described in Chapter 2, as well as for comparison to the Ri-based DNA vaccine vectors described in
Chapter 3. pCP40 (Remaut et al., 1983) was used in Chapter 3 as the source of the runaway R1 replicon. pDMB02-
GFP is the runaway Ri-based DNA vaccine vector that was constructed and characterized in Chapters 3 and 4. A
derivative of pDMB02-GFP with a GTG-to-ATG mutation in the start codon of repA was also constructed (feature
map not shown). Finally, pETDuet-repA was constructed by cloning repA into the expression vector pETDuet-1
(EMD Millipore; feature map not shown) to overexpress RepA protein as a positive control for the Western blots in
Chapter 3.
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